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Prior studies have demonstrated the effect of diazoxide in protecting against apoptosis via 
mitochondrial KATP channel opening in vitro.  The current investigations are designed to 
determine if sildenafil, a phosphodiesterase-5 inhibitor and known mitochondrial KATP 
channel opener, would protect against chronic doxorubicin cardiomyopathy both in vivo 
and in vitro. 
 
 
xvi 
 
Male ICR mice were randomized to 1 of 4 treatments: saline, sildenafil (0.7 mg/kg IP), 
doxorubicin (5 mg/kg IP), and sildenafil (0.7 mg/kg IP)+doxorubicin. Apoptosis was 
determined using the terminal deoxynucleotidyl transferase–mediated dUTP nick-end 
labeling and in situ oligo ligation methods. Desmin distribution was determined via 
immunofluorescence. Bcl-2 was analyzed by Western blot. Left ventricular function was 
measured in Langendorff mode. Electrocardiographical analysis measured changes 
indicative of doxorubicin cardiotoxicity (ST-prolongation). In vitro studies using adult 
ventricular cardiomyocytes were exposed to doxorubicin (1 µM), sildenafil (1 µM) with or 
without NG-nitro-L-arginine methyl ester (L-NAME; 100 µM)), or 5-hydroxydecanoate (5-
HD; 100  µM)) 1 hour before doxorubicin and incubated for 18 hours.  
 
Doxorubicin-treated mice demonstrated increased apoptosis and desmin disruption, which 
was attenuated in the sildenafil+doxorubicin group. Bcl-2 decreased in the doxorubicin 
group but was maintained at basal levels in the sildenafil+doxorubicin group. Left 
ventricular developed pressure and rate pressure product were significantly depressed in 
the doxorubicin group but attenuated in the sildenafil+doxorubicin group. ST-interval 
significantly increased in the doxorubicin group over 8 weeks. In the 
sildenafil+doxorubicin group, ST-interval remained unchanged from baseline. Doxorubicin 
significantly increased apoptosis, caspase-3 activation, and disruption of mitochondrial 
membrane potential in vitro. In contrast, sildenafil significantly protected against 
doxorubicin cardiotoxicity; however, protection was abolished by both L-NAME and 5-
HD. Cell viability studies using spectrophotometer and flow cytometric techniques 
xvii 
 
demonstrated that sildenafil did not affect the antitumor efficacy of doxorubicin in PC-3 
cells in vitro.  In fact, flow cytometry data indicate that sildenafil, when combined with 
doxorubicin, was synergistic in the antineoplastic action of doxorubicin.  
 
Prophylactic treatment with sildenafil prevented apoptosis and left ventricular dysfunction 
in a chronic model of doxorubicin-induced cardiomyopathy.   Moreover, these studies 
provide relevant clinical data on the safety and efficacy of sildenafil, leading the way for 
clinical trials in humans receiving doxorubicin chemotherapy.   
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BACKGROUND 
 
 
Heart failure remains a leading cause of morbidity and mortality in the United States, 
affecting approximately 5 million Americans; particularly those age 65 and older.  In 
1995, Medicare spent an estimated $3.4 billion dollars for the treatment of heart failure.  
In 2004, this number increased to $28 billion dollars.  A continually aging population is 
expected to result in a greater number of people afflicted with heart failure, requiring 
costly long-term medical management with unpredictable effect on quality of life [1]. 
 
Etiologies of heart failure development are numerous and involve complex molecular 
mechanisms, not entirely understood.  However, recent advances have expanded our 
knowledge and understanding of the cellular and molecular mechanisms involved in the 
development of heart failure.  For example, progress in primary and secondary prevention 
of coronary artery disease has improved the ability of physicians to target at-risk 
populations who may benefit from early treatment and lifestyle modifications aimed at 
reducing myocardial infarction and the development of ischemic cardiomyopathy.  In 
contrast, prevention of nonischemic cardiomyopathy remains a challenge.  Moreover, 
successful treatment is often palliative unless the patient is able to receive an orthotopic 
heart transplant.  Left ventricular assist devices offer promise as a bridge to 
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transplantation or as destination therapy.  However, despite these modern biomedical 
innovations, a cure is not attainable and both life expectancy and quality of life are 
unpredictable. 
 
Over thirty years ago, the introduction of the anthracycline antibiotics markedly shifted 
the momentum in the battle against cancer.  Doxorubicin, one of the most widely used 
anthracyclines, continues to be a powerful weapon in the treatment of many human 
neoplasms, including Kaposi’s Sarcoma, acute leukemias, lymphomas, stomach, breast, 
and ovarian cancers [2].  Despite its clinical efficacy, doxorubicin is associated with a 
delayed and progressive cardiomyopathy often presenting more than 20 years after 
treatment cessation [3,4,11].  The underlying mechanism of chronic doxorubicin-induced 
cardiomyopathy occurs primarily via the generation of reactive oxygen species (ROS) in 
the cardiomyocyte mitochondria—a mechanism that is separate from its antineoplastic 
activity, which occurs primarily through inhibition of topoisomerase II [5].  Additionally, 
numerous studies involving both in vitro and in vivo models of heart failure link ROS to 
cardiomyocyte apoptosis [6-9].  In fact, it is hypothesized that apoptosis plays a role in 
the development of heart failure via mechanisms that contribute to cardiomyocyte loss, 
eventually leading to structural changes maladaptive to normal cardiac physiological 
demands [10].  Over the past three decades, significant research has focused on 
unraveling this conundrum.  More recently, a prospective study evaluating cardiac 
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abnormalities in childhood survivors of cancer 15 years or more after treatment with 
doxorubicin, demonstrated an increased incidence of cardiomyopathy at doses much 
lower than the current acceptable total cumulative dose of approximately 450 mg/m2 
[11,12].  In fact, the prevalence of severe cardiac dysfunction was found in more than six 
percent of patients at 15 years post-treatment at doses less than 250 mg/m2.  Moreover, 
the mean prevalence of severe cardiac dysfunction in patients receiving more than 250 
mg/m2 was found to be 19% at 25 years after treatment.  Overall, after an average 
follow-up of 18 years, 39% of childhood cancer survivors treated with doxorubicin 
exhibited severe cardiac dysfunction.  Additionally, severe cardiac dysfunction was 
identified in 6% of patients who had no prior clinical history of cardiac failure with doses 
of doxorubicin at or above 150 mg/m2 without evidence for threshold.  [11] 
 
Despite advances in understanding this disease process at the cellular and molecular 
level, prophylactic pharmacological agents are lacking.  Because of the potency, broad 
spectrum, and efficacy of doxorubicin in treating many malignancies today, coupled with 
the difficulty in treating patients with doxorubicin-induced cardiomyopathy, it is 
imperative that the development of novel approaches aimed at prevention of 
cardiotoxicity is aggressively pursued.  The ideal agent must prevent cardiotoxicity while 
maintaining effective anti-neoplastic activity
  
4 
PHARMACOLOGY OF DOXORUBICIN 
 
Mechanism 
Doxorubicin is an anthracycline antibiotic, isolated from Streptomyces peucetius var 
caesius.  There are three major actions that account for the anti-neoplastic activity and 
toxicity of doxorubicin: (1) high affinity DNA binding via intercalation and interaction 
with topoisomerase II, ultimately blocking the synthesis of both DNA and RNA; (2) 
binding to cellular membranes with alteration of fluidity and ion transport; and (3) redox 
cycling of doxorubicin to its semiquinone free radical with subsequent generation of 
oxygen radicals.   Additionally, several hypotheses have been proposed to explain the 
acute and chronic cardiotoxicity of doxorubicin; these include formation of free radicals, 
inhibition of enzymes and proteins, changes in cardiac muscle gene expression, 
alterations of mitochondrial membrane function, sensitization of Ca2+ release from 
sarcoplasmic reticulum channels, mitochondrial DNA damage, and dysfunction.  [12-
15,58]  
 
It is thought that doxorubicin alone is responsible for acute cardiotoxicity. In contrast, 
chronic cardiotoxicity is believed to be a result of chronic, perpetual redox cycling of 
doxorubicin in the mitochondria—a process that continues long after serum 
concentrations become undetectable.   
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Pharmacokinetics 
In the clinical setting, doxorubicin is administered by intravenous (IV) injection.  The 
usual dose is 60 mg/m2 IV every three weeks to a maximum dose of 450-550 mg/m2.  
However, smaller, more frequent doses (once per week) are commonly used depending 
on type of malignancy, overall chemotherapeutic regimen, prior history of anthracycline 
exposure, and cardiac risk factors.  After IV administration, peak serum concentrations of 
doxorubicin are attained rapidly.  Thirty minutes after infusion, serum concentration 
drops by approximately 50%.  However, significant levels persist for up to 20 hours.  The 
main route for doxorubicin metabolism is via the liver where it undergoes reduction and 
hydrolysis of ring substituents.  The alcohol metabolite of doxorubicin, doxorubicinol, is 
pharmacologically active.  In contrast, the aglycone derivative is an inactive metabolite.  
The majority of doxorubicin and its metabolites are excreted in the bile with a minute 
amount excreted in the urine.  Enterohepatic recirculation of toxic metabolites occurs 
during biliary excretion.  Therefore, dose reduction needs to be considered in patients 
with hepatic disease or elevated hepatic transaminases.  [16] 
 
 
 
 
 
 
  
6 
CELLULAR AND MOLECULAR MECHANISMS OF DOXORUBICIN 
CARDIOTOXICITY 
 
Multiple studies substantiate the major role that reactive oxygen species (ROS) play in 
the development of heart failure both in vivo and in vitro [17,18].  In fact, substantial 
evidence exists implicating the generation of ROS as the underlying mechanism for the 
development of dilated cardiomyopathy and heart failure from multiple etiologies 
including chemotherapy-induced [14,17,18].  Moreover, prior studies have identified the 
mitochondria as the main target of doxorubicin accumulation in cardiac cells [19].  In 
fact, mitochondrial concentrations of doxorubicin (5-50 uM) are several-fold greater than 
simultaneous clinically relevant serum concentrations (0.1-1 uM) [20].  
Mitochondrial NADH dehydrogenase is a major contributor to doxorubicin-generated 
reactive oxygen species (ROS) production via redox cycling of doxorubicin to its 
semiquinone [21, Figure 1].  
 
Figure 1A. Redox cycling of doxorubicin                                                                                                                                     
& formation of Superoxide. 
              #  2005 Patrick William Fisher, DO, PhD 
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Figure 1B. Redox cycling of doxorubicin and formation of ROS & RNS.  
#  2005 Patrick W. Fisher, DO, PhD 
 
It is therefore, not surprising that high mitochondrial concentrations of doxorubicin, 
relative to simultaneous serum concentrations, rapidly perpetuates the formation of free 
radicals.  Compared with other organs such as the liver, the heart possesses a relatively 
limited supply of catalase and glutathione peroxidase (GSH-Px), key intracellular free 
radical scavengers.  Because of chronic doxorubicin free radical production in the heart, 
the supply of both GSH-Px and catalase is rapidly expended; thus, creating an 
environment that promotes hydroxyl radical production [22].  
      NO 
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Accordingly, the accumulation of ROS results in dissipation of the mitochondrial 
membrane potential (!"m), direct activation of the mitochondrial permeability transition 
pore (MPTP), and release of cytochrome-c with subsequent activation of caspase-9 and 
caspase-3 followed by DNA fragmentation consistent with apoptosis [34]. 
 
 
 
Figure 2.  Cell signaling pathways involved in doxorubicin-induced cardiotoxicity. 
#  2005 Patrick W. Fisher, DO, PhD 
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APOPTOSIS 
 
 
It is well known that doxorubicin-induced cardiomyocyte apoptosis occurs via both the 
extrinsic and intrinsic pathways [23,24].  However, it remains unknown whether one 
pathway is more important than the other in respect to doxorubicin-induced cardiomyocyte 
apoptosis.  However, recent studies substantiate the significance of the intrinsic pathway of 
apoptosis in this pathophysiological process [25,26]. 
 
Apoptosis, commonly known as programmed cell death, is a regulated cellular process 
dependent on ATP [27].  It results in cell death for reasons that often are required in 
maintaining normal physiological function in many species.  For example, apoptosis plays 
an important role in the degeneration of the human thymus gland.  Additionally, apoptosis 
is critical in sloughing of intestinal epithelial tissue, which rapidly turns over multiple 
times a year in humans [28].  Distinguishing apoptotic cell death from necrotic cell death 
and DNA repair mechanisms has remained controversial [29].  However, it is now possible 
to delineate these two very different modes of cell death through the implementation of 
several sensitive and specific assays.  The most well defined method for determining 
apoptosis from necrosis is by morphological evaluation [30].  Apoptosis is recognized by a 
series of well-defined morphological changes that differ from necrotic cell death [31].  In 
apoptosis, common morphological findings include condensed heterochromatin often 
observed in the perinuclear regions of the cardiomyocyte, cell shrinkage, nuclear pyknosis, 
and late fragmentation into apoptotic bodies [31].  In contrast, necrotic cell death is 
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characterized by cell membrane disruption and release of intracellular contents that are 
toxic to surrounding cells and tissues [31]. 
 
Apoptosis contributes to the development of heart failure via mechanisms that contribute 
to a loss of cardiomyocytes over time, leading to structural changes that often are 
maladaptive to normal cardiac physiological demands [6,10].  Furthermore, it is also 
suggested that the major difference between whether cells undergo apoptosis versus 
necrosis is the cellular availability of ATP [32].  Since apoptosis is an energy dependent 
process requiring ATP, cells originally destined for programmed cell death may undergo 
necrotic cell death if depleted of adequate ATP stores [32].  
 
Extrinsic Pathway of Apoptosis [Figure 3] 
 
The extrinsic pathway is initiated via binding of a death ligand to a cell surface receptor.  
The ligand is usually one of two different types.  The Fas ligand (Fas-L), otherwise known 
as CD95 or Apo-1, is an integral membrane protein found on the surface of another cell (T-
Lymphocyte).  On the other hand, a ligand may exist as an extracellular protein such as 
tumor necrosis factor-alpha (TNF-$).  Upon ligand-receptor binding, the death-inducing 
signaling complex (DISC) is formed.  For example, the binding of Fas-L to the Fas 
receptor results in recruitment of the Fas-associated death domain (FADD).  Consequently, 
the recruitment of caspase-8 by FADD results in cleavage of the procaspase to its active 
form.  Activated caspase-8 can directly activate caspase-3 while completely bypassing the 
mitochondrial death pathway.  However, active caspase-8 can also activate the BH3 
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interacting death domain agonist (Bid), a proapoptotic Bcl-2 (B cell leukemia/lymphoma-
2) protein, which links the extrinsic to the intrinsic pathway of apoptosis. Both in vivo and 
in vitro studies of acute doxorubicin cardiotoxicity have demonstrated involvement of both 
TNF-alpha and FAS/FAS-L in this process.  [33,34, Figure 3] 
 
 
Figure 3. Simplified Version of the Entrinsic Pathway of Apoptosis in Doxorubicin 
Cardiotoxicity and the Illustration of the Key Link Betweeen Extrinsic and Intrinsic 
Pathways. #  2005 Patrick W. Fisher, DO, PhD 
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Intrinsic Pathway of Apoptosis [Figure 4] 
 
The intrinsic pathway of apoptosis is more complex than the extrinsic pathway and is 
stimulated by a multitude of various extracellular stimuli and intracellular signaling 
mechanisms [33,36].  Extracellular stimuli include growth-factor withdrawal or complete 
deficit of trophic factors or nutrients, ionizing radiation, and chemicals such as toxins.  
Intracellular stimuli include oxidative stress, DNA damage, physical stress on the cytosolic 
matrix proteins that provide a support or scaffold for cells such as myocytes, or oxidation 
of fatty acids.  The result of activation of the intrinsic pathway of apoptosis is the release 
of pro-apoptotic proteins, such as cytochrome-c and apoptosis-inducing factor (AIF), into 
the cytosol with activation of caspases and subsequent DNA fragmentation [36]. 
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Figure 4. Simplified Illustration of the Intrinsic Pathway of Apoptosis in Doxorubicin 
Cardiotoxicity.  # 2005 Patrick W. Fisher, DO, PhD 
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KEY MEDIATORS OF APOPTOSIS 
 
Caspases 
Caspases belong to the class of cysteine proteases that cleave substrates after aspartic acid 
residues.  They play a critical role in apoptosis.  Moreover, caspases are synthesized as 
inactive zymogens known as procaspases.  Procaspases contain an N-terminal prodomain 
and a C-terminal catalytic domain.  The catalytic domain consists of a 20 kDa (p20) and a 
10 kDa (p10) subdomain. Caspases can further be divided into upstream versus 
downstream caspases.  Upstream caspases include caspases 2, 8, 9, 10, and 12.  
Downstream caspases include caspases 3, 6, and 7.  These caspases are then converted to 
their respective active forms by proteolytic cleavage after aspartic acid residues, located 
between the prodomain, p20, and p10 subunits.  Caspase-3 is a key effector in the 
apoptotic pathway, amplifying the signal from initiator caspases (such as caspase-8) and 
signifying full commitment to cellular disassembly.  In addition to cleaving other caspases 
in the enzyme cascade, caspase-3 has been shown to cleave poly (ADP-ribose) polymerase 
(PARP), DNA-dependent protein kinase, protein kinase C!, actin, and intermediate 
filaments such as desmin.  Caspase-8 plays a critical role in the early cascade of apoptosis, 
acting as an initiator of caspase activation; whereas, caspase-9 is an integral component of 
the intrinsic pathway of apoptosis where it cleaves procaspase-3 to its active form.  [35,37] 
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Figure 5.  Illustration of caspase-3 and associated subunits.  
# 2005 National Library of Medicine. 
 
In addition, the cleavage of the pro-caspase to its active form has long been regarded as an 
irreversible marker of commitment to apoptotic cell death.  However, more recent studies 
have demonstrated the ability of NO, at physiological concentrations, to directly, but 
reversibly, inactivate caspase-3 (activated cleaved form) via s-nitrosylation at the cysteine 
residue on the p17 subunit [68,71]. 
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Bcl-2 Family of Proapoptotic and Antiapoptotic Proteins 
Bcl-2 is a key regulator of apoptosis and is essential for proper development, tissue 
homeostasis, and elimination of exogenous toxic stimuli.  Bcl-2 is a 26 kDa, anti-apoptotic 
protein, which promotes cell survival via interactions with anti-apoptotic Bcl-2 family 
members.  These include Bax, Bak, Bik, Bad, and Bid.  One of the major functions of Bcl-
2 is prevention of cell death through its ability in blocking the release of cytochrome-c 
from the intramembrane space of the mitochondria.  Bax and Bak are multidomain 
proapoptotic Bcl-2 proteins.  Either Bax or Bak is required for all instances of apoptosis 
mediated via the intrinsic pathway.  Their interaction at the mitochondrial membrane 
contact site contributes to the formation of the voltage-dependent anion channel, or 
VDAC—facilitating the release of cytochrome-c to the cytosol.  [38-41]  
 
Cytochrome-c  
Cytochrome-c is an electron transport protein essential in aerobic energy conversion.  It is 
found in the mitochondrial intermembrane space in mammalian species.  Cytosolic 
cytochrome-c is a key mediator in the intrinsic pathway of apoptosis.  For example, the 
release of cytochrome-c to the cytosol results in the formation of the apoptosome and 
activation of downstream caspase-3; consequently leading to interaction of activated 
caspase-3 with nuclear dsDNA resulting in DNA fragmentation characteristic of apoptosis 
[38,41]. 
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Mitochondrial membrane potential ("m) & Mitochondrial KATP Channels 
The collapse of "%m is a prominent feature of apoptosis, representing an irreversible 
marker of cellular commitment to apoptotic cell death [42].  Moreover, breakdown of the 
mitochondrial membrane potential (""m) may precede nuclear signs of apoptosis, and it 
may be associated with Ca2+ homeostasis.   
Prior research using the mitoKATP channel opener, diazoxide, demonstrated a link between 
mitoKATP channel opening and preservation of mitochondrial integrity, maintenance of 
mitochondrial membrane potential, and inhibition of cytochrome-c translocation to the 
cytosol following in vitro oxidative stress [43].  Moreover, the opening of mitoKATP 
channels is critical in mediating the cardioprotective effect induced by pathophysiological 
stressors and pharmacological agents.  The activation of these channels is triggered by a 
drop in tissue ATP levels, which result in preventing the dissipation of the mitochondrial 
membrane potential and inhibition of apoptosis [43,44]. 
Furthermore, studies by Marban et al have shown that opening of mitochondrial KATP 
channels by diazoxide induced a cardioprotective effect, which was abolished by 5-
hydroxydeconate (5HD), an inhibitor of the mitoKATP channel [44].  These findings have 
been reported in several other studies of ischemia/reperfusion injury in animal models 
where post-ischemic functional recovery significantly improved and infarct size was 
reduced [42]. 
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Because of the key role of mitochondrial bioenergetics in cellular respiration and in 
mitigating apoptosis, it is a promising target for potential development of novel therapeutic 
applications in cardioprotection. 
 
Intermediate filaments and Mitochondrial Permeability Transition Pore (MPTP) 
Formation 
Intermediate filaments play an integral role in cellular structure and function.  Desmin, an 
intermediate filament found in cardiomyocytes is localized to the Z-line where it supports 
cellular integrity and stabilization of actin filaments [Figure 6A].  Moreover, desmin 
integrates physical contraction of the myofibril via its linkage to adjacent myofibrils.  In 
addition to attachment to the Z-line, desmin also tethers the myofibrils to the sarcolemma, 
nuclei, and to the mitochondria [Figure 6B].  In fact, desmin attaches to the mitochondrial 
membrane contact sites, the same location where the VDAC and mitochondrial 
permeability transition pore (MPTP) are formed [45].  Furthermore, desmin plays a vital 
role in protecting the structural integrity of the myofibrils during mechanical stress.  It is 
conceivable that disruption of desmin either through repeated strain on the contractile 
apparatus resulting from impaired contractility or through direct cleavage from activated 
caspases may contribute to MPTP formation, cytochrome-c release, and apoptosis [Figure 
6].  [45-51]   
 
Although it is known that cardiomyocyte apoptosis contributes to dilated cardiomyopathy 
and heart failure, there is increasing evidence that intermediate filaments such as desmin 
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are involved in this pathological process [45].  Recently, Dinsdale et al [46] demonstrated 
caspase-cleavage of intermediate filaments during apoptosis, which subsequently formed 
intracytoplasmic aggregates.  Moreover, a study using a transgenic mouse model (desmin -
/-) of desmin-related cardiomyopathy (DRM) demonstrated the ability of Bcl-2 
overexpression in preventing DRM as evidenced by prevention of cardiomyocyte 
apoptosis and preservation of cardiac contractility [45].  In addition, Wang et al [47] 
demonstrated the disruption of desmin and formation of intracytoplasmic aggregates in a 
mouse model of desmin-related cardiomyopathy.  Furthermore, Heling et al [48] illustrated 
the disorganization and accumulation of desmin in explanted human heart specimens from 
patients with dilated cardiomyopathy.  
 
Morphological changes including disruption of normal desmin distribution in myocytes as 
observed in DRM are similar to those seen in other forms of cardiomyopathy and heart 
failure [49].  Because intermediate filaments participate in the transmission of active force 
[50], it is plausible that disruption of the filamentous network involving desmin may 
significantly impair contractile force and result in sarcomere fragility. 
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Figure 6A.  Main Intermediate Filaments and Cytoskeletal Proteins Linking the Extracellular Matrix with 
the Structural Muscle Proteins Associated with Mutations Causing Cardiac and Skeletal Myopathy.   
& 2000 Massachusetts Medical Society, Dalakas, MC et al. N Engl J Med 2000; 342: p778. 
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Figure 6B.  Role of desmin in myofibrillar integrity. The mechanism of caspase-3 
cleavage of desmin is depicted.  Caspase-3 cleavage of desmin results in disruption of 
normal contractile function and propagation of apoptosis via its interaction with the 
mitochondria at the site of the MPTP (mitochondrial contact sites).  
#  2005 Patrick W. Fisher, DO, PhD 
 
 
 
. 
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MECHANISMS FOR PREVENTION OF DOXORUBICIN-INDUCED 
CARDIOTOXICITY 
 
Free Radical Scavengers & Iron Chelators 
Most studies focusing on the development of pharmaceuticals aimed at preventing 
doxorubicin cardiotoxicity have targeted mechanisms involved in production of free 
radicals.  Despite some success in pre-clinical experiments, many of these agents have 
significant clinical disadvantages.  For example, probucol, a lipid-lowering antioxidant, 
confers significant protection against doxorubicin-induced cardiotoxicity [56].  However, 
concerns about its high-density lipoprotein lowering properties and its potential to cause 
QT-interval prolongation discourage its application in cancer patients [57].  The 
cytoprotective drug amifostine is less potent than dexrazoxane (Zinecard), an iron chelator, 
and it does not prevent the mortality and weight loss caused by doxorubicin in 
spontaneously hypertensive rats [57,58].  In fact, it has also been shown to have some 
benefit on prevention of acute doxorubicin cardiotoxicity but not on chronic cardiotoxicity 
[59].  Finally, dexrazoxane, the only cardioprotective drug currently available clinically, 
only reduces 50% of doxorubicin-related cardiac complications [60].  Moreover, it 
interferes with the antitumor activity of anthracycline antibiotics and potentiates the 
hematotoxicity of doxorubicin [60]. 
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Other potential pharmacological agents are free radical scavengers such as melatonin and 
5-hydroxymethylrutoside.  However, these agents have limitations in respect to dose and 
frequency and concentration.  Furthermore, clinical investigations are necessary to prove 
their efficacy and safety in humans.  [52,58]  
 
 
Type-5A Phosphodiesterase Inhibition 
Type-5 phosphodiesterase enzyme inhibitors are a class of drugs currently used clinically 
to treat erectile dysfunction and pulmonary hypertension [71].  Because of the mechanism 
of action, these agents show promise for potential targeting of cellular mechanisms that 
promote doxorubicin-generated free radicals.   
Phosphodiesterase enzymes convert the intracellular second messengers cyclic AMP and 
cyclic GMP to the corresponding nucleotides AMP and GMP. There are now 11 
phosphodiesterase families, many of which exist as splice variants. The cAMP-specific 
enzymes include phosphodiesterase 4 (PDE4), -7 and -8. The cGMP-specific PDE’s are 
PDE5, -6 and -9, whereas PDE1, -2, -3, -10 and -11 use both cyclic nucleotides [35]. Most 
known PDE5 inhibitors compete with the substrate cGMP for binding to the protein at the 
catalytic site. Although cGMP binding to the catalytic site stimulates cyclic-nucleotide 
binding to the allosteric sites, inhibitors do not elicit the same property, and Ser92 
phosphorylation has no effect on inhibitor binding.  PDE5 is the primary cGMP-
hydrolyzing activity in human corpus cavernosum tissue. [60] 
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Vasodilatory Effects of cGMP 
Intense research in vascular smooth muscle physiology beginning more than two decades 
ago lead to the discovery of sildenafil citrate, the first synthetic PDE-5 inhibitor for the 
treatment of erectile dysfunction in men.  Initial clinical studies using sildenafil focused on 
its efficacy in treating systemic hypertension and coronary angina.  The hypothesis behind 
these early investigations stemmed from the theory that elevating cGMP levels via PDE-5 
inhibition would result in systemic arterial vasodilatation.  Although the results from early 
studies using sildenafil for the treatment of coronary angina were disappointing, the side-
effect of penile erection, reported by many patients enrolled in this trial, inspired an 
exciting new area of research leading to advancement in the treatment of patients with 
erectile dysfunction [61,62]. 
 
Erection or tumescence is a neurovascular reflex mediated by smooth muscle 
relaxation/contraction in cavernosal tissue [63].  Cavernosal smooth muscle cells are 
normally in a “contracted state”, mediated via $-adrenergic neural stimuli with subsequent 
phosphorylation of Ca+2/calmodulin-dependent myosin light chain kinase.  In contrast, 
tumescence is stimulated by parasympathetic CNS output via neural release of 
acetylcholine.  Consequently, NO is released from non-adrenergic, non-cholinergic 
cavernosal nerves subsequently activating soluble guanylyl cyclase, the enzyme that 
converts GTP to cGMP.  The cyclic nucleotide then stimulates protein kinase G (PKG), 
which initiates a protein phosphorylation cascade.  This results in a decrease in 
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intracellular levels of calcium ions, leading ultimately to dilation of the arteries that bring 
blood to the penis and compression of the spongy corpus-cavernosum. This compression 
contracts veins, reduces outflow of blood, and increases intracavernosal pressure, 
ultimately resulting in tumescence.  A PDE-5 inhibitor will retard enzymatic hydrolysis of 
cGMP to 5’GMP in the human corpus cavernosum, leading to the same outcome. [63] 
 
Role of Nitric Oxide (NO) 
 
Nitric Oxide is well recognized as a key mediator in cell signaling processes.  It is 
produced from L-arginine through chemical reaction catalyzed by at least four major 
isoforms of NOS, i.e. neuronal (nNOS), inducible (iNOS), endothelial (eNOS), and 
mitochondrial NOS (mtNOS). In cellular studies, treatment with doxorubicin at 5 #M for 
24 h increased the amount of iNOS protein without affecting either eNOS or nNOS 
expression in H9C2 rat cardiac cells [105]  The reduction in cardiac contractility in animals 
given doxorubicin at 20 mg/kg i.p., was associated with a 3-4 fold increase in the 
immunopositivity of myocardial iNOS (33±18 vs. 9±2%) and 3-nitrotyrosine formation 
(56±24 vs. 0.3±0.4%) compared with the control group [106].   Pacher et al [107] reported a 
decrease in ejection fraction and cardiac output which coincided with the increase in 
cardiac nitrotyrosine synthesis in mice 5 days after the administration of doxorubicin at 25 
mg/kg (IP).  In these studies, iNOS (–/–) mice treated with doxorubicin displayed improved 
cardiac function versus iNOS (+/+) litters. These findings suggest that the production of 
peroxynitrite (ONOO-) by anthracyclines via iNOS was the critical mechanism of drug-
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induced cell injury in myocytes.  In addition, it is suggested that elevated eNOS expression 
and subsequent NO synthesis in bovine aortic endothelial cells was a result of doxorubicin-
induced hydrogen peroxide production.  
 
Pharmacology of Sildenafil 
Sildenafil citrate (Viagra ®) is an orally administered drug used for the treatment of 
erectile dysfunction in men.  It is a potent type-5 phosphodiesterase inhibitor, which blocks 
the breakdown of cGMP.  In humans, sexual arousal or stimulation results in release of NO 
from penile vascular tissue increasing cGMP production with a subsequent cascade of 
events resulting in: (1) vascular smooth muscle relaxation in the corpus cavernosa, (2) 
engorgement of the lacunae, (3) compression of veins involved in draining blood from 
cavernosal tissue, and ultimately (4) penile rigidity.  [63] 
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Pharmacokinetics of Sildenafil 
After oral administration, sildenafil reaches peak plasma concentration within 
approximately sixty minutes.  Oral administration results in a bioavailability of 
approximately 40% with 96% protein-bound.  The half-life of sildenafil ranges between 
three to five hours with clinical effects lasting 12 hours on average.  
Sildenafil is metabolized by the liver and primarily excreted in the feces with a small 
amount excreted in urine.  The primary hepatic metabolism occurs by microsomal P450 
enzymes (isoenzyme 3A4 and to a lesser extent, 2CA).  Dose adjustment is warranted in 
patients with hepatic disease, or who take any potent inhibitors of the P450 3A4 isoenzyme 
including: (1) ketoconazole, (2) cimetidine, or (3) erythromycin to name a few.  
Furthermore, because sildenafil is protein bound, caution should be used in patients taking 
medicine that is also highly protein bound such as digoxin, amiodarone, or warfarin.   
According to Shabsigh [61], the side-effect profile of sildenafil in patients with hepatic 
impairment or who currently take inhibitors of P450 3A4 isoenzymes did not differ from 
the general population despite significantly elevated plasma concentrations. 
 
In addition to studies in humans, sildenafil has been shown to enhance nitric oxide (NO)-
driven cGMP accumulation in the corpus cavernosum of rabbits without affecting cAMP 
formation. In the absence of NO drive, sildenafil had no functional effect on rabbit isolated 
corpus cavernosum but potentiated the relaxant effects of NO on these tissues.  
Furthermore, it has been shown that sildenafil causes mild to moderate decreases in 
systolic and diastolic pressure because of the inhibition of PDE-5 in smooth muscle cells in 
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the vascular bed.  Prior studies in our laboratory confirmed the mild effect of sildenafil on 
systemic hemodynamics in rabbits.  [64] 
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SPECIFIC AIMS 
 
In the present study, a series of novel investigations designed to examine the effect of 
PDE-5 inhibitors in preventing doxorubicin-induced cardiotoxicity in mice was proposed.  
Preliminary studies conducted in our laboratory by Fisher et al suggest the viability of our 
major hypothesis that PDE-5 inhibitors may confer significant protection against 
doxorubicin-induced cardiomyopathy, when administered in a prophylactic manner.  The 
purpose of this application is to show the effect of sildenafil on doxorubicin-induced 
cardiomyocyte apoptosis and to attain a better understanding of the potential signaling 
pathways in the heart that lead to cardioprotection in a chronic model of doxorubicin-
induced cardiotoxicity.  
 
Accordingly, the main goals of the present study were:  
 
1. To determine whether suppression of PDE-5 with the novel inhibitor, sildenafil, 
attenuates doxorubicin-induced cardiotoxicity and contractile dysfunction via inhibition 
of cardiomyocyte apoptosis in the heart. The effect of clinically relevant doses of 
sildenafil on doxorubicin-induced cardiomyocyte apoptosis both in vivo and in vitro, 
myocardial contractile dysfunction, and of Bcl-2 protein expression was investigated.  It 
was further that PDE-5 inhibition would inhibit doxorubicin-induced apoptosis via opening 
of mitochondrial KATP channels; thereby preventing the collapse of mitochondrial 
membrane potential (""m) and preventing opening of the mitochondrial permeability 
transition pore (MPTP). 
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2. To investigate if PDE-5 suppression will prevent myofibrillar disarray commonly 
associated with cardiomyopathies.  More specifically, the effect of prophylactic treatment 
with sildenafil, at clinically relevant doses, on doxorubicin-induced disruption of desmin in 
cardiomyocytes was examined.  Moreover, it was proposed that PDE-5 inhibition would 
attenuate the disruption of the normal desmin network in the heart, which is vital in 
maintenance of myofibrillar integrity and myocardial contractility.  Sildenafil-induced 
opening of mitochondrial KATP channels, preservation of the mitochondrial membrane 
potential, prevention of the MPTP formation, and subsequent caspase-3 activation 
followed by DNA damage consistent with apoptosis will demonstrate this.  The initial 
hypothesis suggested that the latter would be prevented by increased Bcl-2 protein 
expression ultimately inhibiting the translocation of Bax/Bad to the mitochondrial contact 
site where the MPTP is located. 
 
3.  To evaluate the effect of PDE-5 inhibition in preventing chronic doxorubicin-induced 
cardiotoxicity without affecting doxorubicin’s antineoplastic activity.  To test this 
hypothesis, the viability of PC-3 prostate cancer cells in vitro after treatment with 
sildenafil plus doxorubicin, sildenafil alone, and with doxorubicin alone was studied.  The 
initial hypothesis was that the efficacy of doxorubicin in killing PC-3 cells, at a clinically 
relevant dose (1uM), will not adversely affect prophylactic treatment with sildenafil.   
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The aforementioned studies are the first to demonstrate the protective effect of PDE-5 
inhibition in doxorubicin-induced cardiotoxicity in the heart at both the cellular and sub-
cellular level. Moreover, this is the first study to demonstrate the prevention of 
doxorubicin-induced cardiomyopathy coupled with the inability of sildenafil, at clinically 
relevant doses, in adversely affecting the antineoplastic activity of doxorubicin. 
 
Additionally, these  studies provide relevant data setting the foundation for clinical trials 
 
in humans receiving doxorubicin chemotherapy for hematological and/or oncological neoplasms.
 
Furthermore, these studies provide novel insights into expanding the utility of PDE-5 
 
inhibitors their current use in the treatment of erectile dysfunction (ED) in men.
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METHODS (In Vivo Model) 
 
   
All animal studies were performed in accordance with the guidelines of the National 
Institutes of Health (NIH) “Guide for the Care and Use of Laboratory Animals”, the 
American Physiological Society and the Virginia Commonwealth University. 
Adult male ICR mice (~33 grams each) were randomized to one of four groups.  Group 1 
saline only and served as a control.  Group 2 received sildenafil (0.7 mg/kg i.p.) one hour 
prior to the administration of an equivolume of saline in place of doxorubicin.  Group 3 
received an equivolume of saline one hour prior to doxorubicin (5 mg/kg i.p.).  Group 4 
received sildenafil (0.7 mg/kg i.p.) one hour prior to administration of doxorubicin (5 
mg/kg i.p, Sigma Chemicals, St. Louis, MO).  Animals were housed in a 12:12 hour 
light/dark cycle, temperature-controlled room. Diet consisted of normal mouse chow 
(Harlan, Indianapolis, IN) and water ad libitum.   
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Figure 7. Experimental protocol. Treatment was administered on days 0, 7, and 14. 
Groups II and IV were administered sildenafil 1 hour before either saline or doxorubicin, 
respectively. Group III received saline 1 hour before doxorubicin. ECG (lead II) was 
performed 2 days after each treatment and 1 week thereafter for 8 weeks. LV indicates left 
ventricular. 
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Cardiomyocyte Apoptosis 
 
 
Cardiomyocyte apoptosis was evaluated via the terminal dUTP nick-end labeling method 
(TUNEL) using the ApopTag® In Situ Apoptosis Detection Kit (Chemicon, Temecula, 
CA) according to the manufacturer’s instructions.  The quantification of apoptosis or 
Apoptotic Index (AI) was determined by counting TUNEL (+) myocyte nuclei from ten 
random fields per section and expressed as a percentage of total myocyte nuclei.  Because 
the TUNEL assay can detect DNA damage from non-apoptotic stimuli, complementary 
analysis was conducted using the ApopTag® In Situ Oligo Ligation (ISOL) technique 
(Chemicon, Temecula, CA).  The ISOL method uses T4 DNA ligase to specifically ligate 
DNAase Type I ends to biotin-labeled hairpin oligonucleotides.  The localization of 
oligonucleotides (labeled) is restricted to regions of chromatin characteristic for apoptosis.  
The ISOL method does not label nicks, gaps, or ssDNA, 3’recessed ends or 3’overhanging 
ends longer than one dT base.  These techniques have been used together for appropriate 
labeling of DNA characteristic of apoptosis [56,74-75]. 
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Desmin Immunofluorescence  
 
Distribution of desmin, an intermediate filament important in cellular integrity and 
myocyte contraction, was analyzed in frozen sections (5 #m) in animals from each of the 
experimental groups.  After appropriate fixation in 4% paraformaldehyde, samples were 
incubated for one hour with 10% normal goat serum. Next, primary goat anti-desmin 
antibody (Santa Cruz Biotech, Santa Cruz, CA), diluted 1:50 was applied to each slide and 
incubated for one hour at room temperature.  After several washes, Alexa Fluor 488 
donkey anti-goat secondary antibody (Molecular Probes, Eugene, OR), diluted 1:400 was 
applied to each slide.  Samples were incubated for one hour at room temperature.  After 
several washes in 1X PBS, Prolong Gold® Antifade (Molecular Probes, Eugene, OR) was 
applied followed by mounting with a glass coverslip.  Visualization of desmin distribution 
was accomplished using a Nikon epifluorescent microscope with a 60X oil objective and a 
FITC filter cube.  Image acquisition was obtained using MicroPublisher® 3.3 CCD camera 
with Q-Capture® Professional image analysis software (QImaging, Burnaby, B.C. 
Canada).   
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Analysis of BCL-2 Expression 
 
Mice whole heart proteins were extracted with RIPA buffer (Upstate™, Charlottesville, 
VA) and proteins were separated on SDS-PAGE and transferred onto 12% nitrocellulose 
membranes (Bio-Rad, Hercules, CA). Primary antibodies against Bcl-2 (Molecular weight: 
28kDa) were followed by secondary rabbit IgG-conjugated horseradish peroxidase 
antibody according to manufacturer’s instructions (Santa Cruz Biotech, Santa Cruz, CA).  
Antibodies against '-actin  (Molecular weight: 39 kDa) were used for determination of 
protein loading (Santa Cruz Biotech, Santa Cruz, CA).  Densitometry was performed using 
BioQuant® software (BioQuant, Nashville, TN). 
 
Hemodynamics 
 
Animals (n = 6/group) were sacrificed at 2,4 and 8 weeks after the last day of treatment 
(day 14).  After adequate anesthetization using pentobarbital (100 mg/kg i.p), the heart was 
excised and immediately placed in cold saline (4°C).  The heart was then cannulated via 
the aorta and retrogradely perfused at a constant perfusion pressure equivalent to 100 
cmH2O.  All hearts were perfused with modified Krebs-Henseleit (K-H) buffer at 37°C, 
containing (in mM) 118.5 NaCl, 25.0 NaHCO3, 3.2 KCl, 1.19 MgSO4, 1.25 CaCl2, 1.2 
KH2PO4, and 11 glucose and was bubbled with 95% O2-5% CO2 mixture.  The pH was 
maintained at 7.4.  After the heart began spontaneous contraction, a small incision was 
made in the left atrium.  A latex balloon connected to a pressure transducer via 
polyethylene cannula was inserted through the left atrium and mitral valve into the left 
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ventricle. The balloon was filled with enough water to increase end-diastolic pressure 
(EDP) to approximately 10 mmHg.  Left ventricular systolic pressure (LVSP), left 
ventricular developed pressure (LVDP), and heart rate (HR) were recorded (Chart 4.0, AD 
Instruments, Colorado Springs, CO). LVDP was calculated by subtracting EDP from the 
LVSP.  Rate pressure product (RPP), an index of myocardial oxygen demand and 
workload, was calculated by multiplying LVDP with HR.  Coronary flow reserve was 
measured by timed collection of coronary effluent.  Care was taken to maintain 
temperature of the heart at 37°C. 
 
Electrocardiography 
 
A separate set of four groups (n=6/group) was utilized for the assessment of 
electrocardiographic (ECG) changes indicative of doxorubicin cardiotoxicity [76,77].  
More specifically, this technique will further confirm the presence of doxorubicin-induced 
cardiotoxicity throughout the course of the investigation (10 weeks) as initially proposed 
by Fisher.  All animals were weighed at baseline and every 7-10 days for 8 weeks prior to 
the ECG analysis.  Animals were anesthetized using pentobarbital (50 mg/kg IP) followed 
by insertion of electrodes in the left front limb, right front limb, left hind limb, and right 
hind limb.  The electrodes were connected to an electrocardiography module (LDS Life 
Science, Valley View, CA) and data was recorded for 2-3 minutes per animal. The ST-
interval was measured in five consecutive complexes using Ponemah® physiology 
software (LDS Life Science, Valley View, CA).  ST-interval duration was measured at 
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baseline, 48-72 hours after each dose of doxorubicin (Days 0, 7, and 14 ± 2-3 days) and 
every 7-10 days thereafter until 8-weeks was attained. 
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METHODS (In Vitro Model) 
 
Isolation of Adult Cardiomyocytes 
 
Adult male outbred ICR mice (Harlan, Indianapolis, IN) were used in isolation of 
ventricular myocytes.  Ventricular myocytes were isolated using an enzymatic technique.  
Briefly, mice (n = 3/experiment) were anesthetized with pentobarbital (100 mg/kg IP) and 
the heart was quickly removed from the chest.  Within 3 minutes, the aortic opening was 
cannulated and placed onto a Langendorff perfusion system.  Next, the heart was 
retrogradely perfused (37°C) at a constant pressure of 55 mmHg for 5 minutes with a Ca+2 
-free bicarbonate-based buffer containing (in mM): 120 NaCl, 20 NaHCO3, 5.4 KCl, 1.2 
MgSO4, 1.2 NaH2PO4, 5.6 glucose, 10 2,3-butanedione monoxime, and 5 taurine, which 
was gassed with 95% O2-5% CO2 mixture.  The enzymatic digestion was commenced by 
adding collagenase type II (Worthington, 0.5 mg/ml each) and protease type XIV (0.02 
mg/ml) to the perfusion buffer and continued for ~15 minutes.  Following initial enzymatic 
digestion, 50 #M Ca+2 was added to the enzyme solution and the heart was perfused for 
an additional 10-15 minutes.  Digested ventricular tissue was cut into chunks and gently 
aspirated with a transfer pipette for facilitating cell dissociation.  The cell pellet was 
resuspended for a 3-step Ca+2 restoration procedure (i.e. 125, 250, 500 #M Ca+2).  
Freshly isolated cardiomyocytes were suspended in minimal essential medium (Sigma, 
Catalogue # M1018, pH 7.35-7.45) containing 1.2 mM Ca+2, 12 mM NaHCO3, 2.5% fetal 
bovine serum, and 1% penicillin-streptomycin.  Cells were plated onto 2-chamber slides, 
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which were pre-coated with 20 #g/ml mouse laminin in PBS + 1% penicillin-streptomycin 
for 1 hour.  Cardiomyocytes were cultured in the presence of 5% CO2 for 1 hour in a 
humidified incubator at 37°C.  Myocyte cultures were randomly assigned to one of 12 
treatments: (1) control; (2) sildenafil (1 #M); (3) doxorubicin (1 #M); (4) sildenafil (1#M) 
one hour prior to doxorubicin (1#M);  (5) 5-Hydroxydecanoate (5-HD), a mitoKATP 
channel blocker (100 #M); (6) 5-HD (100 #M) one hour prior to doxorubicin (1 #M); (7) 
5-HD (100 #M)+ sildenafil (1 #M); (8) 5-HD (100 #M)+sildenafil (1 #M) one hour prior 
to doxorubicin (1 #M); (9) NG-nitro-L-arginine methyl ester (L-NAME), a nitric oxide 
synthase (NOS) inhibitor (100 #M); (10) L-NAME (100 #M) one hour prior to 
doxorubicin (1 #M); (11) L-NAME (100 #M)+ sildenafil ( 1 #M); or (12) L-NAME (100 
#M)+ sildenafil (1 #M) one hour prior to doxorubicin (1#M).  Slides were incubated for 
18 hours followed by several washes in 1X PBS prior to analysis. 
 
Cardiomyocyte Apoptosis (In Vitro) 
 
Cardiomyocyte apoptosis was evaluated via the terminal dUTP nick-end labeling method 
(TUNEL) using the ApoAlert™ DNA Fragmentation Assay Kit (BD Biosciences, Palo 
Alto, CA) according to manufacturer’s instructions. Equilibration buffer was used in place 
of working TdT reagent for use as a negative control.  DNAase-I was applied and used as a 
positive control.  Analysis was performed using a Nikon epifluorescent microscope with 
20x objective. A FITC filter cube was utilized in detection of apoptotic myocyte nuclei.  
An ultraviolet filter cube was utilized in detection of DAPI-stained myocyte nuclei.  
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Apoptotic index (AI) was determined from counting TUNEL-positive myocyte nuclei from 
ten separate fields per treatment and expressed as a percentage.  
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Active Caspase-3 Detection 
 
Active Caspase-3 staining was determined using the CaspaTag™ In Situ Assay Kit 
(Chemicon, Temecula, CA) according to manufacturer’s instructions.  This assay is based 
on Fluorochrome Inhibitors of Caspases (FLICA). The inhibitor binds covalently to the 
active caspase.  This kit uses a carboxyfluorescein-labeled fluoromethyl ketone peptide 
inhibitor of caspases-3 and -7 (SR-DEVD-FMK), which emits a red fluorescence. The SR-
DEVD-FMK probe enters each cell and covalently binds to reactive cysteine residue on the 
large subunit of the active caspase heterodimer, thereby inhibiting enzymatic activity.  The 
bound labeled reagent is retained within the cell. The red fluorescent signal is a direct 
measure of active caspase-3 in the cell at the time the reagent was added.  After application 
of CaspaTag™ reagent and Hoechst, cells were immediately examined using a Nikon 
epifluorescent microscope with rhodamine (Active Caspase-3) and ultraviolet (Hoechst) 
bandpass filters.  
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Assessment of Mitochondrial Membrane Potential (!"m) 
 
Loss of ""m was assessed using epifluorescent microscopy.  Cultured adult mouse 
ventricular myocytes were stained with 5,5’, 6,6’-tetrachloro-1, 1’, 3,3’-
tetraethylbenzimidazole-carbocyanide iodine (JC-1, Biocarta, San Diego, CA) after an 18 
hour incubation.  Cells were incubated with 2 #g/ml JC-1 for 10 minutes at 37ºC.  After 
washing with 1xPBS, cells on chamber slides were scanned with a Nikon epifluorescent 
microscope using a 20x objective lens.  Fluorescence was analyzed using a Texas Red-
FITC filter cube.  Red emission of the dye represented a potential-dependent aggregation 
in the mitochondria, reflecting ""m.  Green fluorescence represented the monomeric form 
of JC-1, appearing in the cytosol after mitochondrial membrane depolarization.  The ratio 
of mitochondrial aggregates (red) to the monomeric form of JC-1 (green) was analyzed 
using Q-Capture® Professional image analysis software (QImaging, Burnaby, B.C. 
Canada).  Myocytes were counted from ten separate fields per group and expressed as a 
ratio of mitochondrial aggregates to the monomeric form of JC-1. 
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Cell Viability Assay  
 
In order to determine if sildenafil affects the antitumor efficacy of doxorubicin, a highly 
effective and accurate technique, using PC-3 prostate cancer cell line was utilized.  PC-3 
prostate cancer cells (American Cell Culture, Manassas, VA), which are p53-deficient and 
susceptible to doxorubicin, were cultured in F12-K medium supplemented with 10% fetal 
bovine serum. Approximately 4,000 PC-3 cells/well were plated into one-half of a 96-well 
dish while the other half of the 96-well dish was incubated with 8,000 PC-3 cells/well and 
allowed to attach overnight. Lane 1 consisted of PC-3 cells plus culture media alone.  Lane 
2 was treated with doxorubicin (80 nM).  Lane 3 was treated with doxorubicin (1 uM).  
Lane 4 was treated with sildenafil (1 uM) one-hour before doxorubicin (80 nM).  Lane 5 
was treated with sildenafil (1 uM) one-hour before doxorubicin (1 uM).  Lane 6 was 
treated with sildenafil (1 uM).  Lane 7 was treated with sildenafil (10 uM).  Wells 1-3 & 7-
9 of Lane 8 were treated with sildenafil (10 uM) one-hour before doxorubicin (1 uM).  
Wells 4-6 & 10-12 of Lane 8 were treated with PC-3 cells in culture media only. Cell 
viability or the number of surviving cells was measured 4 days after doxorubicin 
application with CellTiter-Blue( Cell Viability Assay according to manufacturer 
instructions (Promega).  CellTiter-Blue( reagent (20ul/well) was added and incubated for 
one-hour before recording absorbance at 570nm and 600 nm using a VersaMax microplate 
reader with SoftMaxPro software (Molecular Devices).  The average absorbance (600nm) 
values of the culture medium background was subtracted from all 570nm values of 
experimental wells.  Next, the 570-600nm absorbance versus concentration of test 
compound was analyzed. The CellTiter-Blue( Cell Viability Assay uses the indicator dye, 
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resazurin, to measure the metabolic activity of cells as an indicator of cell viability.  Viable 
cells, for example, are capable of reducing resazurin to the highly fluorescent resafurin. 
Because non-viable cells cannot reduce resazurin to resafurin, the fluorescence or 
absorbance is negligible.  The absorbance obtained from this assay is proportional to the 
number of viable cells.   
 
Flow Cytometry 
To confirm our results demonstrating the inability of sildenafil in affecting the antitumor 
efficacy of doxorubicin in vitro using PC-3 cancer cells, we subsequently measured cell 
viability using flow cytometry (Beckman Coulter Flow Cytometer; 488nm laser). 
Calibration for doxorubicin autofluorescence and propidium iodide was conducted before 
analysis.  The experimental groups included: control, doxorubicin (1, 2 and 5 µM), 
sildenafil (1 and 2 µM), doxorubicin (1 #M)+ sildenafil (1 or 10 #M), doxorubicin (2 
#M)+sildenafil (1 or 10 #M), and doxorubicin (5 #M)+sildenafil (10 #M).  In this 
approach, instead of using a compound that is actively reduced by viable cells (resazurin), 
we utilized the impermeable nucleic acid dye, propidium iodide (Sigma-Aldrich), to detect 
the amount of non-viable cells.  Since non-viable cells would have disruption of their 
nuclear membrane, it is expected that necrotic cells would actively stain with propidium 
iodide and be detected using flow cytometry.  Controls containing doxorubicin only, 
doxorubicin + propidium iodide, propidium iodide + media, and media only were added as 
additional controls. Flow cytometric data are depicted in Appendix E. 
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Statistics 
 
 
Data are presented as mean ± SEM.  Difference between groups was analyzed with 
unpaired t test or one-way ANOVA followed by Tukey-Kramer HSD post-hoc test (JMP, 
Version 5, SAS Institute Inc., Cary, NC). P<0.05 was considered as statistically significant. 
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RESULTS (In Vivo) 
 
Cardiomyocyte apoptosis 
 
Prior studies have implicated cardiomyocyte apoptosis in the development of chronic 
cardiomyopathy induced by doxorubicin administration [75,76].  The following results 
indicate the powerful cardioprotection of sildenafil via mitigation of cardiomyocyte 
apoptosis in the experimental group receiving sildenafil.  Data from both TUNEL and 
ISOL techniques demonstrated significant cardiomyocyte apoptosis in doxorubicin group 
compared to saline control at 2, 4, 6, and 8-weeks post-treatment (P<0.001).  Sildenafil 
attenuated doxorubicin -induced cardiomyocyte apoptosis when administered one hour 
before each of three separate treatments with doxorubicin (5 mg/kg IP; 15 mg/kg total 
cumulative dose). These results were similar to saline control animals [Figure 8 A-D]. 
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Figure 8A.  Apoptotic Index using both TUNEL and ISOL techniques in experimental 
groups at (A) 4 and (B) 6 weeks post treatment. 
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Figure 8B.  Apoptotic Index using both TUNEL and ISOL techniques in experimental 
groups at (C) 8 and (D) 10 weeks.  
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Bcl-2 expression  
 
The Bcl-2 family of proteins provides maintenance of the integrity of the outer 
mitochondrial membrane [78].  Pro-apoptotic Bcl-2 family of proteins including Bax, Bak, 
and t-Bid can integrate into the outer mitochondrial membrane in response to apoptotic 
stimuli inducing cytochrome-c release via mitochondrial transition permeability pore 
(MPTP) formation [79, Figure 10].  However, binding of Bcl-2 or Bcl-XL inhibits 
membrane integration of pro-apoptotic Bcl-2 family of proteins and subsequent MPTP 
formation. [80, 81].  In the present study, a significant decrease in Bcl-2 expression was 
observed at 2-weeks and 8-weeks post treatment in the doxorubicin group compared to 
both sildenafil + doxorubicin and control group.  Moreover, Bcl-2 expression was 
maintained when sildenafil was given one hour before doxorubicin treatment [Figure 9].  
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Figure 9. Western Blot of Bcl-2 Protein at 2 Weeks after Treatment (week 4), (A) and 8 
weeks after treatment (week 10) (B).  Bar Graph represents densitometric quantification 
from 3 individual hearts per group, which is normalized against the actin level for each 
sample.  Data are Mean±SEM.  Abbreviations are defined in Figure 7 legend. 
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Figure 10.   Illustration demonstrating the effect of PDE-5A inhibition on mitochondrial 
bioenergetics in the presence of doxorubicin.  &  2005 Patrick W. Fisher DO, PhD. 
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Doxorubicin-induced myofibrillar disarray (desmin distribution) 
 
At 8-weeks post treatment, doxorubicin group exhibited myofibrillar disarray as evidenced 
by abnormal desmin distribution, lack of Z-line integrity, and abnormal cytoplasmic 
desmin aggregation. In contrast, sildenafil+doxorubicin group displayed normal desmin 
distribution as evidenced by immunofluorescent staining throughout the entire cytoplasm 
with clear delineation of Z-lines.  This was similar to both control and sildenafil +saline 
groups. [Figure 11] 
Furthermore, PDE-5A expression was significantly reduced in the doxorubicin-only group 
at 8 weeks post treatment.  This reduced expression and lack of localization to the z-line 
was most marked in the area of the cardiomyocyte where desmin disruption was evident 
[Appendix B, C]. 
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Figure 11.  Immunofluorescent staining for desmin (green) in cryo-sections from mice in 
the saline control (A), sildenafil (B), sildenafil+doxorubicin (C), and doxorubicin (D & E) 
groups at 8 weeks after treatment.  In control, sildenafil, and sildenafil+doxorubicin groups 
(A, B, C), desmin staining is present throughout the entire cytoplasm and is observed at the 
Z-lines demonstrated as green striations (arrowheads). In the doxorubicin-treated group  
(D, E), obvious disruption of the desmin network is present, with loss of Z-line 
localization. Areas of decreased uptake of anti-desmin antibody are apparent (star). 
Nucleus (N).  Magnification X600; E, image acquired with a Zeiss LSM 510 Confocal 
Microscope (Figure E: &  2005 Patrick W. Fisher, DO, Phd)  
E 
N 
N 
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Electrocardiography (ECG)  
 
Prior studies in mice demonstrated a strong correlation between ST-interval duration and 
doxorubicin-induced cardiotoxicity [76,77].  In contrast to ECG recordings in humans, the 
ECG (Lead II) in mice does not contain an ST-segment.  The T-wave immediately follows 
the QRS complex [76,77].  Prolongation of the ST-interval in doxorubicin-treated mice is 
secondary to an increase in action potential duration (APD) [77].  Le Marc et al [82] 
observed an increase in APD in Purkinje fibers after incubation with doxorubicin.  
Furthermore, in isolated cardiomyocytes exposed to doxorubicin, Jabr et al [83] observed 
APD prolongation resulting from doxorubicin -generated ROS.  In experimental groups 
receiving doxorubicin, a significant progressive increase in ST-interval was observed at all 
time points compared to baseline [Figure 12].  Moreover, the most marked increase in ST-
interval occurred between week 4 and week 8.  Furthermore, ECG’s of the control and 
sildenafil+ doxorubicin group did not change during the course of the study.  Sildenafil 
significantly protected against ST-interval prolongation throughout the study period. 
[Figure 12] 
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Figure 12. Electrocardiographical Analysis of ST-Prolongation in mice (lead II). Effect of 
sildenafil on ST-interval prolongation after doxorubicin treatment. ST interval was 
measured with the use of lead II. A, ST-interval prolongation over time. Representative 
tracings of control (B), sildenafil+doxorubicin (C), and doxorubicin only (D) are shown. 
Data are mean±SEM (n=6/group). Abbreviations are as defined in Figure 7 legend. 
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Effect of sildenafil on cardiac function in doxorubicin-treated animals 
 
Our data shows a significant decline in LVDP in the saline+ doxorubicin group compared 
to control at 2 weeks post treatment (27% vs control; 24% vs sildenafil+ doxorubicin) 
[Table 1].  Decline in contractility as measured by rate pressure product (RPP) persisted 
through 8 weeks after treatment cessation in the saline+ doxorubicin group. Animals 
treated prophylactically with sildenafil before doxorubicin demonstrated RPP that 
remained unchanged from control over 8-week post-treatment period.  
[Figure 13] 
 
 
Figure 13.  Bar graph representing rate pressure product in mouse hearts via Langendorff 
mode at 4, 6, and 10-weeks post-treatment. Data are mean ± SEM (n = 6/group/time point).
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Table 1.  Hemodynamic Indices  
                        Week 2                  Week 4            Week 8
 
                HR      LVDP       RPP               HR        LVDP        RPP             HR        LVDP       RPP 
Group    (bpm)    (mmHg)  (mmHg•min-1)       (bpm)      (mmHg) (mmHg•min-1)    (bpm)    (mmHg) (mmHg•min-1)
 
Control     384±4      99±3     35116±1121       410±1         92±1      34851±1057        412±8        90±1     34159±651 
SIL           393±5     101±3   36905±1342*    399±11      106.6±3   39762±1588*     412±4†       93±1    35296±437* 
DOX    439±11* 72±4*    28099±1562*    374±13*     68±4*    22108±1248*†   365±15*†    62±3*† 19716±947*† 
SIL+DOX   381±6**  95±3** 33471±1290**  381±11**  102±3      35861±1238**   409±2**     92±1   34827±413** 
 
* P <0.05 vs. control, ** P <0.05 vs. DOX, † P <0.001 vs. Week 2. 
 
Abbreviations: HR= heart rate; LVDP= left ventricular developed pressure; RPP= rate pressure product; 
SIL= sildenafil+saline; SIL+DOX= sildenafil+doxorubicin; DOX= saline+doxorubicin 
 
&  2005 Patrick W. Fisher, DO, PhD. 
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RESULTS (IN VITRO) 
 
Cardiomyocyte Apoptosis 
 
Treatment of cardiomyocytes with doxorubicin (1 #M) for 18 hours resulted in a 
significant increase in TUNEL (+) nuclei as indicated by Apoptotic Index (AI) of 0.61 ± 
0.09%, which was similar to both L-NAME+sildenafil+doxorubicin (0.62±0.08%) and 5-
HD+sildenafil+doxorubicin (0.60±0.10%) groups.  In contrast, a significant inhibition of 
apoptosis was evident in the sildenafil+doxorubicin (0.078±0.031%) group, which was 
similar to control (0.078 ± 0.032%) [Figure 14].  Additionally, active caspase-3 expression 
increased in the doxorubicin, sildenafil+L-NAME+ doxorubicin, and 5HD+sildenafil+ 
doxorubicin groups compared to sildenafil+ doxorubicin and control groups. [Figure 15] 
 
        
 
Figure 14.  Apoptotic Index of Adult Ventricular Myocytes (TUNEL). 
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Figure 15A. Activated caspase-3 in adult mouse ventricular myocytes (red; left 
column) with myocyte nuclei stained with Hoechst (blue; right column). A, 
Control; B, doxorubicin; C, sildenafil plus doxorubicin; Magnification x200; n=3. 
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Figure 15B.  Activated Caspase-3 in Adult Ventricular Cardiomyocytes 
D, sildenafil (1 µM); E, L-NAME (100 µM) plus sildenafil plus doxorubicin; F,    
5-HD (100 µM) plus sildenafil (1 µM) plus doxorubicin. Magnification x200; n=3. 
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Assessment of Mitochondrial Membrane Potential (!"m) 
 
Exposure of adult mouse ventricular myocytes to doxorubicin (1 µM) for 18 hours resulted 
in dissipation of !"m as illustrated via JC-1 immunofluorescent staining [Figure 16].  In 
contrast, myocytes pretreated with sildenafil (1 µM) before treatment with doxorubicin 
demonstrated preservation of the !"m.  The latter result was similar to both control and 
sildenafil+ doxorubicin groups [Figure 17].  However, dissipation of !"m occurred in 
both the L-NAME (100 µM)+sildenafil+ doxorubicin and 5-HD (100 µM)+sildenafil+ 
doxorubicin groups. [Figure 16] 
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Figure 16.  Effect of Sildenafil on ""m in Adult Ventricular Cardiomyocytes.  Red 
Fluorescence represents the mitochondrial aggregate form of JC-1, indicating intact 
mitochondrial membrane potential.  Green Fluorescence represents the monomeric 
form of JC-1, indicating dissipation of ""m. A, Control; B, sildenafil (1 #M); C, 
doxorubicin (1 #M); D, sildenafil (1 #M) plus doxorubicin (1 #M); E, L-NAME (100 
#M) plus sildenafil plus doxorubicin; F, 5-HD (100 #M) plus sildenafil plus 
doxorubicin.
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Figure 17.  Ratio of Mitochondrial Aggregates to the Monomeric Form of JC-1.  Data are 
expressed as Mean ± SEM.   
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Effect of Sildenafil on the Antitumor Efficacy of Doxorubicin 
 
Cell Viability Assay 
Using absorbance as a measure of cell viability, the administration of doxorubicin at a 
concentration of 80 nM did not significantly inhibit the growth of PC-3 cells in vitro.  In 
contrast, doxorubicin at a concentration of 1 uM significantly decreased the ability of PC-
3 cells to reduce resaruzin to the highly fluorescent resafurin.  In other words, 
doxorubicin at a concentration of 1 uM killed approximately 65% of PC-3 cells when 
administered alone.  Additionally, the administration of sildenafil at concentrations of 
either 1 uM or 10 uM one-hour before the administration of doxorubicin, did not effect 
the antitumor efficacy of doxorubicin in PC-3 cells in vitro.  Moreover, when sildenafil (1 
uM or 10 uM) was administered alone, the viability of PC-3 cells was not significantly 
altered.  
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Figure 18.  Photograph of 96-well Microplate used in the Cell Viability Assay of 
sildenafil on the antitumor efficacy of doxorubicin. Lane 1 & Lane 8 (Wells 4-6 &10-12), 
Media only; Lane 2, DOX (80 nM); Lane 3, DOX (1 uM); Lane 4, sildenafil 
(1uM)+DOX (80 nM); Lane 5, sildenafil (1 uM)+DOX (1 uM); Lane 6, sildenafil (1 uM), 
Lane 7, sildenafil (10 uM); Lane 8 (Wells 1-3 & 7-9), sildenafil (10 uM)+DOX 1 uM). 
© 2005 Patrick William Fisher, DO, PhD 
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Figure 19.  Cell Viability of PC-3 Prostate Cancer Cells (in vitro).  The absorbance is 
proportional to the number of viable cells. ! 2005 Patrick W. Fisher, DO, PhD. 
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Figure 20. Flow cytometry data assessing the percentage of cell death in PC-3 prostate 
cancer cells in vitro after treatment with varying concentrations of doxorubicin with or 
without sildenafil, A.  Cell death (% of PC-3 prostate cancer cells) versus doxorubicin 
concentrations (1, 2, and 5 µM), B.  Cell Death was determined using propidium iodide 
(50 µg/ml).   Subtraction of doxorubicin autofluorescence was performed prior to flow 
cytometric analysis. Data are Mean +/- SEM.  © 2005 Patrick William Fisher, DO, PhD 
A 
B 
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DISCUSSION 
 
 
For the first time, it is demonstrated that treatment with clinically relevant doses of 
sildenafil (0.7 mg/kg IP) one hour prior to doxorubicin resulted in cardioprotection from 
doxorubicin-induced cardiotoxicity.  More specifically, the aforementioned data illustrate 
the capacity of sildenafil in attenuation of cardiomyocyte apoptosis, maintenance of the 
!"m, preservation of myofibrillar integrity, prevention of left ventricular dysfunction, and 
prevention of ST-prolongation consistent with chronic doxorubicin toxicity 8-weeks after 
the final of three treatments. 
 
The initial hypothesis behind pharmacological preconditioning with sildenafil was that the 
vasodilatory action of sildenafil could potentially release endogenous mediators of 
preconditioning such as adenosine or bradykinin from endothelial cells triggering 
phosphorylation of nitric oxide synthase (NOS) and subsequent release of nitric oxide 
(NO) [63].  The generation of NO could then serve to activate sGC with increased 
formation of cyclic guanyl monophosphate (cGMP).  Increase in cGMP is believed to be 
responsible for activation of protein kinase G (PKG) and subsequent opening of mitoKATP 
channels in acute and delayed cardioprotection [63].  Previously, it was demonstrated that 
sildenafil-induced delayed preconditioning was linked to a NOS-dependent mechanism in 
mice [64].  Moreover, both the acute and delayed cardioprotective effects of sildenafil in 
an in vivo rabbit model were blocked by 5-HD, supporting the significance of mitoKATP 
channel opening in sildenafil-induced cardioprotection. 
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In addition to the present in vivo model of sildenafil-induced cardioprotection from 
doxorubicin as developed by Fisher, an in vitro model of adult mouse ventricular myocytes 
was utilized to further investigate the mechanism of protection by sildenafil.  In this study, 
prophylactic administration of sildenafil inhibited doxorubicin-induced !"m dissipation, 
caspase-3 activation, and cardiomyocyte apoptosis.  This protection was completely 
abolished by both L-NAME and 5-HD.  These findings infer that sildenafil-mediated 
protection from doxorubicin-induced cardiomyocyte apoptosis is NOS-dependent and 
establishes a significant role of mitoKATP channel opening in sildenafil-induced 
cardioprotection. 
 
The exact mechanism of NO/cGMP in protection from doxorubicin cardiotoxicity is not 
fully explicable.  It has been shown that doxorubicin-generated H2O2 induces a massive 
increase in eNOS gene transcription followed by generation of extremely high levels of 
NO favoring potentiation of ROS and reactive nitrogen species [84].  In contrast, exposure 
to low nonlethal levels of endogenous NO induces adaptive responses by continuous 
stimulation of sGC with maintenance of basal cGMP levels, rendering cells resistant to 
lethal concentrations of NO or peroxides [85].  Moreover, it has been reported that 
physiologically stimulated sGC by NO preserved !"m and inhibited apoptosis [86,87] and 
caspase-3 activation [88].  From the current results, it is plausible that pretreatment with 
sildenafil prior to an onslaught of doxorubicin-generated free radicals augments inherent 
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cellular adaptive mechanisms mediated by endogenous NO/cGMP, leading to maintenance 
of mitochondrial bioenergetics and inhibition of apoptosis. 
 
Doxorubicin-induced cardiomyocyte apoptosis occurs via both the extrinsic and intrinsic 
pathways [89,90].  However, using this model substantiates the significance of the intrinsic 
pathway of apoptosis in both normal and pathophysiological processes.  Prior studies have 
identified the mitochondria as the main target of doxorubicin accumulation in cardiac cells 
[91].  Mitochondrial NADH dehydrogenase contributes to doxorubicin-generated ROS 
production via redox cycling of doxorubicin to its semiquinone [92].  Furthermore, 
mitochondrial concentrations of doxorubicin (5-50 µM) are several folds greater than 
simultaneous clinically relevant serum concentrations (0.1-1uM) [93].  Consequently, the 
relatively limited supply of both catalase and glutathione peroxidase (GSH-Px) is rapidly 
expended in the heart; thus creating an environment that promotes hydroxyl radical 
production [94].  Accordingly, the accumulation of ROS results in dissipation of the !"m, 
direct activation of the MPTP, and cytochrome-c release followed by caspase-3 activation 
and DNA fragmentation consistent with apoptosis [95]. 
 
In the present study, a significant decline in Bcl-2 expression both at 2-weeks and 8-weeks 
post treatment in the doxorubicin group compared to the sildenafil+doxorubicin group and 
control was observed, suggesting an important role of Bcl-2 in altering the pathological 
process leading to end-stage heart failure.  Furthermore, significant differences in desmin 
distribution between the doxorubicin group compared to all other groups was evident 
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[FIGURE 11, Appendix B].  In the doxorubicin group, desmin distribution was clearly 
disrupted with areas of decreased staining in the cytoplasm consistent with desmin 
aggregation.  In contrast, sildenafil+doxorubicin group displayed an intact desmin network 
similar to control.  Although it is known that cardiomyocyte apoptosis contributes to 
dilated cardiomyopathy and heart failure, there is increasing evidence that intermediate 
filaments such as desmin are involved in this pathological process [96].  Recently, 
Dinsdale et al [97] demonstrated caspase-cleavage of intermediate filaments during 
apoptosis.  Moreover, a study using a transgenic mouse model (desmin -/-) of desmin-
related cardiomyopathy (DRM) demonstrated the ability of Bcl-2 overexpression in 
preventing DRM as evidenced by prevention of cardiomyocyte apoptosis and preservation 
of cardiac contractility [96].  In addition, Wang et al [98] demonstrated the disruption of 
desmin and formation of intracytoplasmic aggregates in a mouse model of DRM.  
Furthermore, Heling et al [99] illustrated the disorganization and accumulation of desmin 
in explanted human heart specimens from patients with dilated cardiomyopathy.  
Consistent with findings by Heling [99] and Wang [98], we demonstrated disruption of 
desmin in the doxorubicin group compared with the sildenafil+doxorubicin and control 
groups.  Moreover, morphological changes including disruption of normal desmin 
distribution in myocytes as observed in DRM are similar to those seen in other forms of 
cardiomyopathy and heart failure [100].  Because intermediate filaments participate in 
transmission of active force [101], it is plausible that disruption of the filamentous network 
involving desmin may significantly impair contractile force and result in sarcomere 
fragility.  Also, since desmin is known to adhere to the mitochondria in the same location 
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where the MPTP is formed, it is conceivable that disruption of desmin either through 
repeated strain on the contractile apparatus resulting from impaired contractility or through 
direct cleavage from activated caspases may contribute to MPTP formation, cytochrome-c 
release, and apoptosis.  
 
In the current study, an 8-week post-treatment strategy was utilized, which is adequate in 
demonstrating many of the pathological findings of chronic doxorubicin-induced 
cardiotoxicity. Moreover, it provides an animal model that parallels the clinical 
progression of this disease in humans.  In addition, it serves as a unique and powerful 
model to understand many of the common factors that are shared by most forms of clinical 
cardiomyopathies.  
 
Results from in vitro studies using PC-3 cancer cells testing the effect of sildenafil on the 
efficacy of the antineoplastic action of doxorubicin provide relevant pre-clinical safety and 
efficacy data that are required prior to eventual clinical trials in humans.    
 
Because sildenafil has proven to be relatively safe and effective in treating both erectile 
dysfunction and pulmonary hypertension [102,103], it is conceivable that sildenafil may 
provide an additional tool to hematologists and oncologists in preventing cardiotoxicity.  
Moreover, sildenafil prophylaxis during doxorubicin treatment may potentially allow an 
increase in the dose of doxorubicin beyond the cumulative limitation of 450-600 mg/m2 
[104], thereby expanding its therapeutic window. Studies using flow cytometry assessing 
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the cytotoxicity of doxorubicin on PC-3 cancer cells in vitro, demonstrate a powerful 
synergistic effect when sildenafil is combined with doxorubicin.  This in vitro effect of 
sildenafil on the antineoplastic action of doxorubicin is presently being evaluated by Fisher 
et al using an in vivo nude mouse model with subcutaneously injected human breast cancer 
cells known to be susceptible to doxorubicin.   
 
The powerful synergy between doxorubicin and sildenafil in killing PC-3 prostate cancer 
cells in vitro is intriguing.  However, it also raises concerns regarding the possibility of 
potentiating the side effects of doxorubicin in non-cardiac cells where cell turnover is 
considered a normal physiological process.  In the aforementioned chronic mouse model of 
used in our investigations, no evidence of potentiation of doxorubicin toxicity in non-
cardiac cells was observed.  Although not investigated in our model, the addition of 
sildenafil in patients undergoing chemotherapy with doxorubicin may lead to an increase 
in doxorubicin-induced toxicity in hematopoietic stem cells.  This could prove fatal during 
the induction phase of chemotherapy.  Moreover, it may prolong the time that patients 
remain neutropenic, thereby exposing them to the additional risk of opportunistic 
infections.  Further studies are warranted in examining whether this synergistic effect of 
sildenafil with doxorubicin is translated to non-neoplastic cells in humans.   
75 
 
 
The mechanism responsible for the synergy of sildenafil in the presence of doxorubicin in 
PC-3 prostate cells in vitro is not fully explicable.  However, numerous studies using PC-3 
cell lines in examining mechanisms of chemoresistance have elucidated several intriguing 
hypotheses—many implicating NO as a key mediator in chemosensitization [114-119]. 
Moreover, many cancer cells develop chemoresistance by overexpressing Bcl-2 and  
Bcl-XL, key mediators of apoptosis under the transcriptional regulation of NF-)B [115].    
In fact, Huerta-Yepez et al [115] demonstrated the ability of NO donors in down regulating 
the expression of Bcl-XL via inhibition of NF-)B activity resulting in the sensitization of 
cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).  This 
ultimately resulted in activation of the mitochondrial pathway of apoptotic cell death.  
 
Furthermore, there is evidence suggesting that suppression of endogenous nitric oxide may 
play a key role in hypoxia-induced chemoresistance [119].  Moreover, it has been 
demonstrated that hypoxia inducible factor (HIF-1) DNA binding is inhibited by NO in the 
presence of hypoxia [118]. In addition, NO has also been demonstrated to inhibit HIF-1$ 
accumulation in cells under hypoxic conditions [116].  It is therefore not surprising that 
PC-3 cells contain all three well-known isoforms of nitric oxide synthase (NOS): eNOS, 
iNOS, and nNOS [115].  
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In another study by Frederiksen et al [116], exposure of hypoxia to human breast 
carcinoma cells resulted in decreased endogenous cGMP, further implicating the role of 
NO in chemoresistance.  In fact, in a follow-up study, Frederiksen et al provided further 
support implicating that administration of low concentrations of NO mimetic agents can 
prevent acquired drug resistance in PC-3 prostate cancer cells to doxorubicin [114].   
 
In the present studies illustrating the synergistic effect of sildenafil in doxorubicin-induced 
antineoplastic action in PC-3 cells, it is plausible that the inhibition of PDE-5, maintains or 
upregulates production of NO to physiological levels thereby “sensitizing” this cancer cell 
line to doxorubicin-induced cell death.  Further studies will help unravel this conundrum 
and provide a better understanding of the role of PDE-inhibitors in the pathophysiology of 
cell signaling mechanisms involved in the proliferation of many neoplastic diseases. 
 
Future Investigations 
Further studies aimed at attenuating the detrimental effects leading to chronic doxorubicin 
cardiomyopathy should be investigated.  Some of the potential targets include the 
examination of the transcription factors, heat shock factor-1 and GATA-4, in addition to 
heat shock proteins and their relationship with cGMP/sGC in cardiomyocytes. 
 
An early event in the cardiotoxic effect of the antitumor drug doxorubicin is GATA-4 
depletion, which in turn causes cardiomyocyte apoptosis. Studies by Aries et al [110] 
indicate that the transcription factor GATA-4 is antiapoptotic and may be vital for the 
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adaptive stress response of the adult heart. As such, the ability to regulate the genes 
responsible for apoptosis in the heart via transcription factor modulation offers promise in 
the area of heart failure [Figure 21] 
 
The transcription factors GATA-4 and GATA-6 regulate cardiomyocyte hypertrophy in 
vitro and in vivo.  Recent studies have shown that GATA-4 might also play a role in 
survival of adult cardiac myocytes [110,111].  This transcription factor may potentially 
regulate pathophysiological conditions such as myocardial ischemia-reperfusion injury, 
ischemic preconditioning,  and environmental and drug-induced cardiomyopathies where 
apoptosis and survival of cardiac myocytes play an essential role. [112]  
 
Additionally, because of the protective effects of the anti-apoptotic protein, Bcl-2, in 
preventing doxorubicin-induced cardiomyopathy as demonstrated in vivo [113], it would 
be intriguing to ascertain the effect of PDE-5 inhibition in preserving the DNA-binding 
activity of GATA-4 and its subsequent ability to preserve basal levels of Bcl-2 following 
treatment with doxorubicin. Studying the transcription and phosphorylation of GATA-4 in 
vivo can accomplish this.   
 
Moreover, further investigations are warranted that may lead to a better understanding of 
the role and significance of PDE-5 localization in cardiomyocytes in vivo and its 
relationship to subsequent contractile dysfunction.  PDE-5 expression in mouse 
cardiomyocytes has previously been demonstrated in our laboratory by Das et al.  
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Moreover, Takimoto et al [112] have also demonstrated PDE-5 expression in frozen 
sections from adult NOS3 (–/–) mice and their wild-type counterparts.  Furthermore, the 
study by Takimoto et al suggests that the effects of cGMP on PKG-1 activation is 
dependent on z-band localization of PDE-5A, thus enabling modulation of PKA and 
subsequent calcium-induced contractility by sildenafil. Moreover, they suggest that acute 
NOS3 inhibition removes the critical substrate to the PDE-5A complex and thus eliminates 
the antiadrenergic effect of sildenafil. In fact, they infer that chronic NOS3 inhibition or 
the use of NOS3 (–/–) mice results in the loss of PDE-5A from the z-band, resulting in the 
elimination of sildenafil’s effectiveness in maintaining contractility even in the presence of 
exogenous NO.  Although intriguing, their rationale for PDE-5A localization to the z-band 
is not entirely complete.  In recent studies by Fisher [Appendix B, C], clear evidence exists 
demonstrating the loss of PDE-5A expression and lack of localization at the z-band in 
frozen sections from doxorubicin-only treated mice at 8-weeks post-treatment (total 
cumulative dose= 15mg/kg IP).   It is plausible that decreased contractility from desmin 
disruption subsequently results in the inability of PDE-5A from localizing to the z-band.  
Moreover, the ability of caspase-3 in cleavage of desmin at the z-band may be interrelated 
to the inability of PDE-5A in locating to the z-band.  
 
One hypothesis that requires further investigation is that PDE-5A localization to the z-band 
is associated with protection of desmin cleavage by activated caspase-3.  Because NO is 
known to inactivate caspase-3 via reversible binding of NO to the active cysteine residue 
on the large subunit via s-nitrosylation, it is plausible to that maintaining myofibrillar 
79 
 
integrity and contractile function at the z-band is coordinated through PDE-5A inhibition 
with subsequent physiological available “pools” of NO that are available to inactivate the 
detrimental actions of active caspase-3 on myofibrillar disruption of intermediate 
filaments. 
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Figure 21.  Potential targets for further investigation on the molecular mechanisms of 
doxorubicin-induced cardiotoxicity.  
&  2005 Patrick W. Fisher, DO, PhD 
 
 
 
 
81 
 
 
 
 
 
References 
 
 
1. American Heart Association.  Heart Disease and Stroke Statistics--2003 Update. 
Dallas, Tex.: American Heart Association.; 2002. 
 
2. Bristow MR, Billingham ME, Mason JW, Daniels JR. Clinical spectrum of 
anthracycline cardiotoxicity. Cancer Treat Rep. 1978;62:873-879. 
 
3. Steinherz LJ, Steinherz PG, Tan C. Cardiac failure and dysrhythmias 6-19 years 
after anthracycline therapy: a series of 15 patients. Med Pediatr Oncol. 
1995;24:352-61. 
 
4.  Steinherz, LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 
20 years after completing anthracycline therapy. JAMA. 1991;266:672-7. 
 
5. Meyers C. The role of iron in doxorubicin-induced cardiomyopathy. Semin Oncol. 
1998;25:10-14. 
 
6. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998 
Sep 24;339(13):900-5. 
 
7. Kotamraju S, Konorev EA, Joseph J, Kalyanaraman B. Doxorubicin-induced 
apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin 
traps and ebselen. Role of reactive oxygen and nitrogen species.  J Biol Chem. 
2000;275:33585-92.  
 
8. Olson RD, Mushlin PS. Doxorubicin cardiotoxicity: analysis of prevailing 
hypotheses. FASEB J. 1990;4:3076-86. 
 
9. Sawyer DB, Fukazawa R, Arstall MA, Kelly RA. Daunorubicin-induced apoptosis 
in rat cardiac myocytes is inhibited by dexrazoxane. Circ Res. 1999;84: 257-265. 
 
10. Narula J, Haider N, Virmani R, DiSalvo TG, Kolodgie FD, Hajjar RJ, Schmidt U, 
Semigran MJ, Dec GW, Khaw BA. Apoptosis in myocytes in end-stage heart 
failure. N Engl J Med. 1996;335:1182-9. 
 
11.  Pein F, Sakiroglu O, Dahan M, Lebidois J, Merlet P, Shamsaldin A, Villain E, de 
Vathaire F, Sidi D, and Hartmann O. Cardiac abnormalities 15 years and more after 
82 
 
adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut 
Gustave Roussy. Br J Cancer 91: 37-44, 2004. 
 
12. Minow R, Benjamin R, Lee E, Gottlieb J. Adriamycin cardiomyopathy—risk 
factors. Cancer. 1977;39:1397-402. 
 
13. Kotamraju S, Konorev EA, Joseph J, Kalyanaraman B. Doxorubicin-induced 
apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin 
traps and ebselen. Role of reactive oxygen and nitrogen species.  J Biol Chem. 
2000;275:33585-92.  
 
14. Olson RD, Mushlin PS. Doxorubicin cardiotoxicity: analysis of prevailing 
hypotheses. FASEB J. 1990;4:3076-86. 
 
15. Sawyer DB, Fukazawa R, Arstall MA, Kelly RA. Daunorubicin-induced apoptosis 
in rat cardiac myocytes is inhibited by dexrazoxane. Circ Res. 1999;84: 257-265. 
 
16.   Minotti G, Menna P, Salvatorelli E, Cairo G, and Gianni L. Anthracyclines: 
molecular advances and pharmacologic developments in antitumor activity and 
cardiotoxicity. Pharmacol Rev 56: 185-229, 2004. 
 
17. Narula J, Haider N, Virmani R, DiSalvo TG, Kolodgie FD, Hajjar RJ, Schmidt U, 
Semigran MJ, Dec GW, Khaw BA. Apoptosis in myocytes in end-stage heart 
failure. N Engl J Med. 1996;335:1182-9. 
  
18. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 
1998;339:900-5.  
 
19. Sarvazyan N. Visualization of doxorubicin-induced oxidative stress in isolated 
cardiac myocytes. Am J Physiol. 1996;271:H2079-85. 
 
20. Konorev EA, Kennedy MC, Kalyanaraman B. Cell-permeable superoxide 
dismutase and glutathione peroxidase mimetics afford superior protection against 
doxorubicin-induced cardiotoxicity: the role of reactive oxygen and nitrogen 
intermediates. Arch Biochem Biophys. 1999;368:421-8. 
 
21. Davies KJ, Doroshow JH. Redox cycling of anthracyclines by cardiac 
mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. J Biol 
Chem. 1986;261:3060-7. 
  
22. Doroshow JH, Locker GY, Myers CE. Enzymatic defenses of the mouse heart 
against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin 
Invest. 1980;65:128-135. 
83 
 
 
23. Fulda S, Meyer E, Friesen C, Susin SA, Kroemer G, Debatin KM. Cell type 
specific involvement of death receptor and mitochondrial pathways in drug-induced 
apoptosis.  Oncogene. 2001;20:1063-1075. 
 
24. Childs AC, Phaneuf SL, Dirks AJ, Phillips T, Leeuwenburgh C. Doxorubicin 
treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as 
well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-
2:Bax ratio. Cancer Res. 2002;62:4592-8. 
 
 
25. Papadopoulou LC, Theophilidis G, Thomopoulos GN, Tsiftsoglou AS. Structural 
and functional impairment of mitochondria in adriamycin-induced cardiomyopathy 
in mice: suppression of cytochrome c oxidase II gene expression. Biochem 
Pharmacol. 1999;57:481-9. 
 
26. Haunstetter A, Izumo S. Apoptosis: basic mechanisms and implications for 
cardiovascular disease. Circ Res. 1998;82:1111-1129. 
 
27. Soini Y, Paakko P, and Lehto V-P. Histopathological Evaluation of Apoptosis in 
Cancer. Am J Pathol 153: 1041-1053, 1998. 
 
28.   Thompson JS, Saxena SR.  Regulation of intestinal regeneration: new insights.  
Micro Res Tech 2000; 86:129-137. 
 
29.   Elsasser A, Suzuki K, and Schaper J. Unresolved issues regarding the role of 
apoptosis in the pathogenesis of ischemic injury and heart failure. J Mol Cell 
Cardiol 32: 711-724, 2000. 
 
30.   Kang PM, Haunstetter A, Aoki H, Usheva A, and Izumo S. Morphological and 
molecular characterization of adult cardiomyocyte apoptosis during hypoxia and 
reoxygenation. Circ Res 87: 118-125, 2000. 
 
31. Anversa P. Myocyte death in the pathological heart. Circ Res 86: 121-124, 2000. 
 
32. Liu, Kim, CN, Yang, J, Jemmerson, R, Wang, X.  Induction of apoptotic program 
in cell-free extracts: requirement for dATP and cytochrome c.  Cell, 1996; 86: 147-
157. 
 
33. Reed JC. Mechanisms of Apoptosis. Am J Pathol 157: 1415-1430, 2000. 
 
84 
 
34. Nakamura T, Ueda Y, Juan Y, Katsuda S, Takahashi H, and Koh E. Fas-mediated 
apoptosis in adriamycin-induced cardiomyopathy in rats: In vivo study. Circulation 
102: 572-578, 2000. 
 
35.  O'Rourke B. Apoptosis: rekindling the mitochondrial fire. Circ Res 85: 880-883, 
1999. 
 
36. Freude B, Masters TN, Kostin S, Robicsek F, Schaper J. Cardiomyocyte apoptosis 
in acute and chronic conditions.  Basic Res Cardiol. 1998 Apr;93(2):85-9.   
 
37. Marchand EL, Der Sarkissian S, Hamet P, and deBlois D. Caspase-dependent cell 
death mediates the early phase of aortic hypertrophy regression in losartan-treated 
spontaneously hypertensive rats. Circ Res 92: 777-784, 2003. 
 
 38. Mattson, M.P. and G. Kroemer, Mitochondria in cell death: novel targets for 
neuroprotection and cardioprotection. Trends Mol Med 9(5): p. 196-205,2003. 
 
39. Antonsson, B., Mitochondria and the Bcl-2 family proteins in apoptosis signaling 
pathways. Mol Cell Biochem 256-257(1-2): p. 141-55,2004. 
 
40. Hockenbery, D.M., Z.N. Oltvai, X.M. Yin, C.L. Milliman and S.J. Korsmeyer, Bcl-
2 functions in an antioxidant pathway to prevent apoptosis. Cell 75(2): p. 241-
51,1993. 
 
41. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome 
c from mitochondria: A primary site for Bcl-2 regulation of apoptosis. Science 275: 
1132-1136, 1997. 
 
42. Garlid KD, Paucek P, Yarov-Yarovoy V, Murray HN, Darbenzio RB, D'Alonzo 
AJ, Lodge NJ, Smith MA, and Grover GJ. Cardioprotective effect of diazoxide and 
its interaction with mitochondrial ATP-sensitive K+ channels. Possible mechanism 
of cardioprotection. Circ Res 81: 1072-1082, 1997. 
 
43. O'Rourke B. Myocardial K(ATP) channels in preconditioning. Circ Res 87: 845-
855, 2000. 
 
85 
 
44. Akao M, Ohler A, O'Rourke B, and Marban E. Mitochondrial ATP-sensitive 
potassium channels inhibit apoptosis induced by oxidative stress in cardiac cells. 
Circ Res 88: 1267-1275, 2001. 
 
45. Weisleder N, Taffet GE, Capetanaki Y. Bcl-2 overexpression corrects 
mitochondrial defects and ameliorates inherited desmin null cardiomyopathy. 
PNAS. 2004;101:769-774. 
 
46. Dinsdale D, Lee JC, Dewson G, Cohen GM, Peter ME. Intermediate filaments 
control the intracellular distribution of caspases during apoptosis. Am J Pathol. 
2004;164:395-407. 
 
47. Wang X., Osinska H, Dorn GW, Nieman M, Lorenz JN, Gerdes AM, Witt S, 
Kimball T, Gulick J, Robbins J. Mouse model of desmin-related cardiomyopathy. 
Circulation. 2001;103:2402-7. 
 
48. Heling A, Zimmermann R, Kostin S, Maeno Y, Hein S, Devaux B, Bauer E, 
Klovekorn W-P, Schlepper M, Schaper W, Schaper J. Increased Expression of 
Cytoskeletal, Linkage, and Extracellular Proteins in Failing Human Myocardium. 
Circ Res. 2000;86:846-853. 
 
49. Watkins SC, Samuel JL, Marotte F, Bertier-Savalle B, Rappaport L. Microtubules 
and desmin filaments during onset of heart hypertrophy in rat: a double 
immunoelectron microscope study. Circ Res.1987;60:327-36. 
 
50. Watson PA, Hannan R, Carl LL, Giger KE. Desmin gene expression in cardiac 
myocytes is responsive to contractile activity and stretch. Am J Physiol. 
1996;270:C1228-35. 
 
51. Dalakas MC, Park KY, Semino-Mora C, Lee HS, Sivakumar K, and Goldfarb LG. 
Desmin myopathy, a skeletal myopathy with cardiomyopathy caused by mutations 
in the desmin gene. N Engl J Med 342: 770-780, 2000. 
 
52. van Acker FA, van Acker SA, Kramer K, Haenen GR, Bast A, van der Vijgh WJ. 
7-monohydroxyethylrutoside protects against chronic doxorubicin-induced 
cardiotoxicity when administered only once per week. Clin Cancer Res. 
2000;6:1337-41. 
 
53. Jabr RI, Cole WC. Alterations in electrical activity and membrane currents induced 
by intracellular oxygen-derived free radical stress in guinea pig ventricular 
myocytes.  Circ Res. 1993;72:1229. 
 
86 
 
54. Kumar D, Kirshenbaum LA, Li T, Danelisen I, Singal PK. Apoptosis in 
Adriamycin cardiomyopathy and its modulation by probucol. Antioxid Redox 
Signal. 2001;3:135-45.  
 
55. Nazeyrollas P, Prevost A, Baccard N, Manot L, Devillier P, Millart, H. Effects of 
amifostine on perfused isolated rat heart and on acute doxorubicin-induced 
cardiotoxicity.  Cancer Chemother Pharmacol. 1999;43:227-32. 
 
56. Liu X, Chen Z, Chua CC, Ma YS, Youngberg GA, Hamdy R, Chua BH. Melatonin 
as an effective protector against doxorubicin-induced cardiotoxicity. Am J Physiol 
Heart Circ Physiol. 2002;283:H254-263. 
 
57.       Cancer Chemother Pharmacol. 2000;45(4):329-34 
 
58. Koning J, Palmer P, Franks CR, Mulder DE, Speyer JL, Green MD, Hellmann K. 
Cardioxane--ICRF-187 towards anticancer drug specificity through selective 
toxicity reduction. Cancer Treat Rev. 1991;18:1-19. 
 
59. Corbin JD, Francis SH, and Webb DJ. Phosphodiesterase type 5 as a 
pharmacologic target in erectile dysfunction. Urology 60: 4-11, 2002. 
 
60. Lincoln TM. Cyclic GMP and phosphodiesterase 5 inhibitor therapies: what's on 
the horizon? Mol Pharmacol 66: 11-13, 2004. 
 
61. Ignarro LJ, Bush PA, Buga GM, Wood KS, Fukuto JM, and Rajfer J. Nitric oxide 
and cyclic GMP formation upon electrical field stimulation cause relaxation of 
corpus cavernosum smooth muscle. Biochem Biophys Res Commun 170: 843-850, 
1990. 
 
62. Shabsigh R. Therapy of ED: PDE-5 Inhibitors. Endocrine 23: 135-141, 2004. 
 
63. Kukreja RC, Ockaili R, Salloum F, Yin C, Hawkins J, Das A, and Xi L. 
Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning 
strategy. J Mol Cell Cardiol 36: 165-173, 2004. 
 
64. Salloum F, Yin C, Xi L, Kukreja RC. Sildenafil induces delayed preconditioning 
through inducible nitric oxide synthase-dependent pathway in mouse heart. Circ 
Res. 2003;92:595-7.  
 
65.  Kalivendi SV, Kotamraju S, Zhao H, Joseph J, Kalyanaraman B. Doxorubicin-
induced apoptosis is associated with increased transcription of endothelial nitric-
oxide synthase. Effect of antiapoptotic antioxidants and calcium. J Biol Chem. 
2001;276:47266-76. 
87 
 
 
66. Paxinou E, Weisse M, Chen Q, Souza JM, Hertkorn C, Selak M, Daikhin E, 
Yudkoff M, Sowa G, Sessa WC, Ischiropoulos H. Dynamic regulation of 
metabolism and respiration by endogenously produced nitric oxide protects against 
oxidative stress. Proc Natl Acad Sci U S A. 2001;98:11575-80. 
 
67.  Nisoli E, Falcone S, Tonello C, Cozzi V, Palomba L, Fiorani M, Pisconti A, 
Brunelli S, Cardile A, Francolini M, Cantoni O, Carruba MO, Moncada S, 
Clementi E. Mitochondrial biogenesis by NO yields functionally active 
mitochondria in mammals. Proc Natl Acad Sci U S A. 2004;101:16507-12. 
 
68.       Beltran B, Mathur A, Duchen MR, Erusalimsky JD, Moncada S. The effect of 
nitric oxide on cell respiration: A key to understanding its role in cell survival or 
death. Proc Natl Acad Sci U S A. 2000;97:14602-7. 
 
71. Kim YM, Talanian RV, Billiar TR. Nitric oxide inhibits apoptosis by preventing 
increases in caspase-3-like activity via two distinct mechanisms. J Biol Chem. 
1997;272:31138-48. 
 
72. Watanabe H, Ohashi K, Takeuchi K, Yamashita K, Yokoyama T, Tran QK, Satoh 
H, Terada H,Ohashi H, Hayashi H. Sildenafil for primary and secondary pulmonary 
hypertension. Clin Pharmacol Ther. 2002;71:398-402.  
 
73. Liu X, Chen Z, Chua CC, Ma YS, Youngberg GA, Hamdy R, Chua BH. Melatonin    
as an effective protector against doxorubicin-induced cardiotoxicity. Am J Physiol 
Heart Circ Physiol. 2002;283:H254-263 
 
74. Didenko VV, Boudreaux DJ, Baskin DS. Substantial background reduction in 
ligase-based apoptosis detection using newly designed hairpin oligonucleotide 
probes. Biotechniques. 1999;27:1130-2. 
 
75. Cesselli D, Jakoniuk I, Barlucchi L, Beltrami AP, Hintze TH, Nadal-Ginard B, 
Kajstura J, Leri A, and Anversa P. Oxidative stress-mediated cardiac cell death is a 
major determinant of ventricular dysfunction and failure in dog dilated 
cardiomyopathy. Circ Res. 2001;89:279-286. 
 
76. van Acker FA, van Acker SA, Kramer K, Haenen GR, Bast A, van der Vijgh WJ. 
7-monohydroxyethylrutoside protects against chronic doxorubicin-induced 
cardiotoxicity when administered only once per week. Clin Cancer Res. 
2000;6:1337-41. 
 
88 
 
77. van Acker SA, Kramer K, Voest EE, Grimbergen JA, Zhang J, van der Vijgh WJ, 
Bast A. Doxorubicin-induced cardiotoxicity monitored by ECG in freely moving 
mice. A new model to test potential protectors. Cancer Chemother Pharmacol. 
1996;38:95-101. 
 
78. Mattson MP, Kroemer G. Mitochondria in cell death: novel targets for 
neuroprotection and cardioprotection. Trends Mol Med. 2003;9:196-205. 
 
79. Antonsson B. Mitochondria and the Bcl-2 family proteins in apoptosis signaling 
pathways. Mol Cell Biochem. 2004;256:141-55. 
 
80. Hockenbery, DM, Oltvai ZN, Yin XM, Milliman CL, Korsmeyer SJ. Bcl-2 
functions in an antioxidant pathway to prevent apoptosis. Cell 1993;75:241-51. 
 
81. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome 
c from mitochondria: A primary site for Bcl-2 regulation of apoptosis. Science. 
1997;275:1132-1136. 
 
82. Le Marc H, Spinelli W, Rosen MR. The effects of doxorubicin on ventricular 
tachycardia.  Circulation.  1986;74:881. 
 
83. Jabr RI, Cole WC. Alterations in electrical activity and membrane currents induced 
by intracellular oxygen-derived free radical stress in guinea pig ventricular 
myocytes.  Circ Res. 1993;72:1229. 
 
84.  Kalivendi SV, Kotamraju S, Zhao H, Joseph J, Kalyanaraman B. Doxorubicin-
induced apoptosis is associated with increased transcription of endothelial nitric-
oxide synthase. Effect of antiapoptotic antioxidants and calcium. J Biol Chem. 
2001;276:47266-76. 
 
85. Paxinou E, Weisse M, Chen Q, Souza JM, Hertkorn C, Selak M, Daikhin E, 
Yudkoff M, Sowa G, Sessa WC, Ischiropoulos H. Dynamic regulation of 
metabolism and respiration by endogenously produced nitric oxide protects against 
oxidative stress. Proc Natl Acad Sci U S A. 2001;98:11575-80. 
 
86.  Nisoli E, Falcone S, Tonello C, Cozzi V, Palomba L, Fiorani M, Pisconti A, 
Brunelli S, Cardile A, Francolini M, Cantoni O, Carruba MO, Moncada S, 
Clementi E. Mitochondrial biogenesis by NO yields functionally active 
mitochondria in mammals. Proc Natl Acad Sci U S A. 2004;101:16507-12. 
 
87.     Beltran B, Mathur A, Duchen MR, Erusalimsky JD, Moncada S. The effect of 
nitric oxide on cell respiration: A key to understanding its role in cell survival or 
death. Proc Natl Acad Sci U S A. 2000;97:14602-7. 
89 
 
 
88. Kim YM, Talanian RV, Billiar TR. Nitric oxide inhibits apoptosis by preventing 
increases in caspase-3-like activity via two distinct mechanisms. J Biol Chem. 
1997;272:31138-48. 
 
89. Fulda S, Meyer E, Friesen C, Susin SA, Kroemer G, Debatin KM. Cell type 
specific involvement of death receptor and mitochondrial pathways in drug-induced 
apoptosis.  Oncogene. 2001;20:1063-1075. 
 
90. Papadopoulou LC, Theophilidis G, Thomopoulos GN, Tsiftsoglou AS. Structural 
and functional impairment of mitochondria in adriamycin-induced cardiomyopathy 
in mice: suppression of cytochrome c oxidase II gene expression. Biochem 
Pharmacol. 1999;57:481-9.  
 
91. Kalyanaraman B, Joseph J, Kalivendi S, Wang S, Konorev E, Kotamraju S. 
Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol Cell Biochem. 
2002;234:119-124. 
 
92. Davies KJ, Doroshow JH. Redox cycling of anthracyclines by cardiac 
mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. J Biol 
Chem. 1986;261:3060-7. 
 
93. Konorev EA, Kennedy MC, Kalyanaraman B. Cell-permeable superoxide 
dismutase and glutathione peroxidase mimetics afford superior protection against 
doxorubicin-induced cardiotoxicity: the role of reactive oxygen and nitrogen 
intermediates. Arch Biochem Biophys. 1999;368:421-8. 
 
94. Doroshow JH, Locker GY, Myers CE. Enzymatic defenses of the mouse heart 
against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin 
Invest. 1980;65:128-135. 
 
95. Childs AC, Phaneuf SL, Dirks AJ, Phillips T, Leeuwenburgh C. Doxorubicin 
treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as 
well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-
2:Bax ratio. Cancer Res. 2002;62:4592-8. 
 
96. Weisleder N, Taffet GE, Capetanaki Y. Bcl-2 overexpression corrects 
mitochondrial defects and ameliorates inherited desmin null cardiomyopathy. 
PNAS. 2004;101:769-774. 
90 
 
 
97. Dinsdale D, Lee JC, Dewson G, Cohen GM, Peter ME. Intermediate filaments 
control the intracellular distribution of caspases during apoptosis. Am J Pathol. 
2004;164:395-407. 
 
98. Wang X., Osinska H, Dorn GW, Nieman M, Lorenz JN, Gerdes AM, Witt S, 
Kimball T, Gulick J, Robbins J. Mouse model of desmin-related cardiomyopathy. 
Circulation. 2001;103:2402-7. 
 
 
99. Heling A, Zimmermann R, Kostin S, Maeno Y, Hein S, Devaux B, Bauer E, 
Klovekorn W-P, Schlepper M, Schaper W, Schaper J. Increased Expression of 
Cytoskeletal, Linkage, and Extracellular Proteins in Failing Human Myocardium. 
Circ Res. 2000;86:846-853. 
 
100. Watkins SC, Samuel JL, Marotte F, Bertier-Savalle B, Rappaport L. Microtubules 
and desmin filaments during onset of heart hypertrophy in rat: a double 
immunoelectron microscope study. Circ Res.1987;60:327-36. 
 
101. Watson PA, Hannan R, Carl LL, Giger KE. Desmin gene expression in cardiac 
myocytes is responsive to contractile activity and stretch. Am J Physiol. 
1996;270:C1228-35. 
 
102. Lim, PH,Moorthy P,Benton KG. The clinical safety of Viagra. Ann N Y Acad Sci. 
2002;962:378-88. 
 
103. Watanabe H, Ohashi K, Takeuchi K, Yamashita K, Yokoyama T, Tran QK, Satoh 
H, Terada H,Ohashi H, Hayashi H. Sildenafil for primary and secondary pulmonary 
hypertension. Clin Pharmacol Ther. 2002;71:398-402. 
 
104. Minow R, Benjamin R, Lee E, Gottlieb J. Adriamycin cardiomyopathy—risk 
factors. Cancer. 1977;39:1397-402. 
  
105. Aldieri, E., L. Bergandi. Doxorubicin induces an increase of nitric oxide synthesis 
in rat cardiac cells that is inhibited by iron supplementation. Toxicol Appl 
Pharmacol.  2002;185:85-90. 
 
106. Pacher, P., L. Liaudet. "Potent metalloporphyrin peroxynitrite decomposition 
catalyst protects against the development of doxorubicin-induced cardiac 
dysfunction." Circulation 2003;107: 896-904. 
 
91 
 
107. Bai, P., J. G. Mabley.Matrix metalloproteinase activation is an early event in 
doxorubicin-induced cardiotoxicity. Oncol Rep 2004;11:505-8. 
 
112. Takimoto E, Champion HC, Belardi D, et al. cGMP catabolism by phosphodiesterase 5A 
regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. Circ Res. Jan 7 
2005;96(1):100-109. 
 
113. Fisher PW, Salloum F, Das A, et al. Phosphodiesterase-5 inhibition with sildenafil 
attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of 
doxorubicin cardiotoxicity. Circulation. Apr 5 2005;111(13):1601-1610. 
 
114. Frederiksen LJ, Siemens DR, Heaton JP, et al. Hypoxia induced resistance to doxorubicin 
in prostate cancer cells is inhibited by low concentrations of glyceryl trinitrate. J Urol. Sep 
2003;170(3):1003-1007. 
 
115. Huerta-Yepez S, Vega M, Jazirehi A, et al. Nitric oxide sensitizes prostate carcinoma cell 
lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl 
expression. Oncogene. Jun 24 2004;23(29):4993-5003. 
 
116. Sandau KB, Fandrey J, Brune B. Accumulation of HIF-1alpha under the influence of nitric 
oxide. Blood. Feb 15 2001;97(4):1009-1015. 
 
117. Denninger JW, Marletta MA. Guanylate cyclase and the NO/cGMP signaling pathway. 
Biochim Biophys Acta. May 5 1999;1411(2-3):334-350. 
 
118. Huang LE, Willmore WG, Gu J, et al. Inhibition of hypoxia-inducible factor 1 activation 
by carbon monoxide and nitric oxide. Implications for oxygen sensing and signaling. J Biol 
Chem. Mar 26 1999;274(13):9038-9044 
 
119. Matthews NE, Adams MA, Maxwell LR, et al. Nitric oxide-mediated regulation of 
chemosensitivity in cancer cells. J Natl Cancer Inst. Dec 19 2001;93(24):1879-1885. 
92 
 
Appendix A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Confocal microscopic image illustrating desmin distribution (green) and DAPI-stained 
nuclei (blue) in a cryosection from a mouse left ventricle at 8 weeks post treatment with 
doxorubicin [Total Cumulative dose= 15mg/kg IP]).  
&  2005 Patrick W. Fisher, DO, PhD. 
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Appendix B 
 
 
 
 
 
 
Confocal microscopic image of cryosection from a mouse left ventricle, demonstrating 
colocalization of desmin (green) with PDE-5A (red)--in a doxorubicin-only treated animal 
8 weeks post treatment (Total cumulative dose = 15 mg/kg IP).  Nuclei are stained blue 
with DAPI.  * Desmin disruption; PDE-5A localization (arrows).   
&  2005 Patrick W. Fisher, DO, PhD. 
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Appendix C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A, Confocal microscopic image of cryosection from a mouse left ventricle, 
demonstrating colocalization of desmin (green) with PDE-5A (red)--in a doxorubicin-
only treated animal 8 weeks post treatment (Total cumulative dose = 15 mg/kg IP).  
Nuclei are stained blue with DAPI. B, Same image without desmin fluorescence; only 
PDE-5A and DAPI-stained nuclei are visible. * Desmin disruption; PDE-5A localization 
(arrows).   &  2005 Patrick W. Fisher, DO, PhD. 
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Confocal microscopic image of cryosection from a mouse left ventricle in a 
doxorubicin-only treated animal 8 weeks post treatment (Total cumulative dose = 15 
mg/kg IP), demonstrating PDE-5A (red), A; Phase image, B; desmin (green), C; Nuclei 
stained with DAPI (blue), D; and merged image of all three fluorophores, E. 
 &  2005 Patrick W. Fisher, DO, PhD. 
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Post-Doctoral Scholar/ Advanced Heart Failure/Heart Transplant Fellow  
                         
Virginia Commonwealth University Medical Center, Richmond, VA   2002-2006 
 
Clinical Cardiology Fellow/COCATS Level III Research Track 
  
Northwestern University Feinberg School of Medicine, Evanston, IL     1999-2002 
 
Internal Medicine Residency  
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GRADUATE EDUCATION  
 
Virginia Commonwealth University School of Medicine,  
Department of Physiology 
 
Doctor of Philosophy in Physiology, May 21, 2005 
 
Concentration: Molecular and Cellular Cardiology 
 
Dissertation Title: Type-5A Phosphodiesterase Inhibition in the Prevention of 
Doxorubicin Cardiomyopathy 
 
Kirksville College of Osteopathic Medicine, Kirksville, MO 
 
Doctor of Osteopathic Medicine, June 6, 1999 
 
 
UNDERGRADUATE EDUCATION 
 
Truman State University, Kirksville, MO 
 
B.S. Biology, Cum Laude, May 7, 1994     
 
 
HONORS & AWARDS 
 
National Heart, Lung, and Blood Institute 
Post-Doctoral Training Grant (2003-2005) 
 
Type T32 (HL07537-15); “Cardioprotective Mechanisms of Myocardial Injury” 
 
Principal Investigator: Michael L. Hess, MD 
 
Co-Principal Investigator: Rakesh C. Kukreja, Ph.D. 
 
Phi Kappa Phi National Honorary Society (Spring 2005)-- Nominated by the 
Department of Physiology at the Virginia Commonwealth University School of 
Medicine 
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GlaxoSmithKline Research & Education Foundation for Cardiovascular Disease 
Young Investigator Award: “New Frontiers in Genomics and Cardiovascular 
Disease”.  (April 8-9, 2005) Philadelphia, Pennsylvania 
 
National Clinical Vignette Award Winner— 
American College of Physicians Annual Sessions 2002 
 
Presidential Scholar, Kirksville College of Osteopathic Medicine (1995 & 1996) 
  
Truman State University Dean’s List (6 Consecutive Semesters) 
 
HONOR SOCIETIES:   
 
1. Sigma Sigma Phi National Osteopathic Honor Society 
 
2. National Order of Omega 
 
3. Blue Key Society 
 
4. Alpha Sigma Alpha National Honor Society 
 
5. Gamma Sigma Alpha Honorary Society 
 
 
 
REFEREE REVIEWER   
 
1. Circulation  
 
2. Journal of Cardiac Failure 
 
3.  American Journal of Kidney Diseases  
 
4. Journal of Thrombosis and Thrombolytics  
 
5. Journal of Clinical Biochemistry  
 
6. Journal of Lasers in Science and Medicine 
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INVITED LECTURES 
 
1. International Society for Heart Research American Section, 27th Annual 
Meeting (May 12th-15th, 2005) 
    New Orleans, LA 
  
    Symposium: Role of Phosphodiesterases in Cardiovascular Disease; 
     
Lecture: Role of PDE-5A Inhibition in Attenuation of Doxorubicin      
Cardiomyocyte Apoptosis and Left Ventricular Dysfunction 
 
2.  American Heart Association Scientific Sessions 2005, Dallas, TX 
 
     Symposium: Type 5A-Phosphodiesterase Inhibitors in Cardiovascular Disease 
     
 Lecture: Role of PDE-5A Inhibition in Attenuation of Doxorubicin 
Cardiomyocyte Apoptosis and Left Ventricular Dysfunction 
 
  
3. Virginia Commonwealth University School of Medicine, Department of 
Physiology/Cardiology Annual Lecture Series (MAY 3, 2005) 
 
     Lecture: Clinical Application of Viagra in Attenuation of Doxorubicin-Induced 
Cardiomyocyte Apoptosis and Left Ventricular Dysfunction 
 
4. Virginia Commonwealth University School of Medicine, Department of 
Physiology Cardiovascular & Exercise Physiology Graduate Course- (Dr. 
Alexandre Fabiato, Course Director) 
 
Lecture:  Pathophysiology of Heart Failure: From Bench to Bedside  
(March 29-31, 2005) 
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RESEARCH EXPERIENCE 
 
Virginia Commonwealth University School of Medicine, Division of Cardiology, 
Richmond, VA (July 2003-July 2006) 
 
 Mentor:  
 Rakesh C. Kukreja, Ph.D. 
 The Eric Lippman Chair of Molecular Cardiology 
 Professor of Medicine, Professor of Biochemistry, Professor of Emergency 
Medicine 
   
Ph.D. Dissertation Title:  Type-5A Phosphodiesterase Inhibition on Prevention 
of Doxorubicin Cardiomyopathy 
 
 
Feinberg Cardiovascular Research Institute, Northwestern University Feinberg 
School of Medicine, Chicago, IL  (June 2000-September 2000) 
 
Mentors: 
Francis J. Klocke, MD, MACC Director, Feinberg Cardiovascular Research 
Institute, Professor of Medicine, Feinberg School of Medicine, Northwestern 
University, Chicago, IL   
 
Robert S. Decker, PhD Professor of Medicine, Professor of Cell and Molecular 
Biology, Feinberg School of Medicine, Northwestern University, Chicago, IL  
 
Investigated the contribution of apoptosis to myocardial contractile 
dysfunction in canine models of low-flow ischemia  
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Evanston Northwestern Healthcare, Evanston, IL Division of Cardiology  
(9/1999-9/2001)  
 
1. Congestive Heart Failure Telemanagement Clinical Outcomes Trial 
 
Mentor: 
Randall E. Williams, MD Associate Professor of Medicine, Feinberg 
School of Medicine Northwestern University, Chicago, IL 
 
 
 
2.  Metoprolol vs. Diltiazem in the Acute Treatment of Ventricular Rate in 
Atrial Fibrillation or Atrial Flutter Using Combination Intravenous and 
Oral Therapy: A Double-Blind, Randomized Controlled  
Clinical Trial Principal Investigator:  Patrick W. Fisher, DO  
 
Mentor:  David M. Najman, MD  Assistant Professor of Medicine, 
Feinberg School of Medicine Northwestern University, Chicago, IL 
 
The MDAFIB Study Investigator Group: Patrick W. Fisher, DO, Tomasz 
Kuzniar, MD, PhD, David You, MD, Kyong Oh, MD, Dawn Lombardo, DO, 
Isabella Rybaltowski, PharmD, Marla N. Fisher, RN, BSN, Rajiv Udani, DO, 
DJ. Anh, MD, and David M.  Najman, MD.  
 
Clinical trial approved December 21, 2000 by the Evanston Northwestern 
Healthcare Institutional Review Board  
 
 
Kirksville College of Osteopathic Medicine, Kirksville MO (1999)   
 
Mentor: 
Martin Schwarze, DO, FACOI, FACC Cardiology Diagnostics, St. Louis, 
MO 
Developed a two-volume evidence-based manual as an addition to the 
core cardiolology curriculum for students and house-staff at the 
Kirksville College of Osteopathic Medicine 
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ABSTRACTS & PRESENTATIONS 
 
 
1. Angiotensin II Receptor Blockade with Losartan Reduces Apoptosis and Infarct 
Size Following Ischemia/Reperfusion in the Rabbit Heart. Okubo S, Fisher PW, 
Salloum F, Ockaili R, Marwaha VR, Ambrosio G, Hess ML, and Kukreja, RC.   
 
Oral Presentation, March 9th, 2005; ACC 2005 Scientific Sessions, Orlando, FL 
 
2. Contribution of Apoptosis to the Contractile Dysfunction During Low-Flow 
Ischemia in the Canine Myocardium. Robert S. Decker, Marlene L. Decker, Patrick 
W. Fisher, Sakie Nakamura, Kathleen R. Harris, and Francis J. Klocke.        
  
Abstract presented at the International Society for Heart Research XVII World 
Congress, July 6-11, 2001 
 
3.  Cardiac Conundrum:  Complications of a Young Woman Twenty Years After 
Receiving Doxorubicin and   Radiation Treatment for Rhabdomyosarcoma.  
Patrick W. Fisher, David M. Najman, and Randall E. Williams. 
 
Abstract accepted as a finalist for the Heart Failure 2001 Annual Symposium, Loyola 
University, Stritch School of Medicine, February 9, 2001 
 
Poster presented at “Challenging Cases in Heart Failure”, Heart Failure 2001 
Symposium, Loyola University, Stritch School of Medicine, February 9, 2001 
 
4.  A Novel Twist To the familial Mediterranean Fever Story: Non-Amyloid 
Nephrotic Syndrome Due to an Unusual Mutation and Fibrillary 
Glomerulonephritis.  Patrick W. Fisher, Tammy Ho, Robert Goldschmidt, Ronald 
Semerdjian, and Gregory W. Rutecki.  
 
Selected as a National Award Winner & Finalist 
 
American College of Physicians-American Society of Internal Medicine (ACP-ASIM) 
2002 Clinical Vignette and Research Competition (April 12-15, 2002) 
Philadelphia, PA 
 
Poster presented orally before three-judge panel at the ACP-ASIM Annual Session, 
April 12, 2002, Philadelphia, PA 
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5.  Why Live on Borrowed Time and ‘Collateral’?  Securing Longevity with 
Preconditioning.  Patrick W. Fisher, David Najman, Timothy A. Sanborn, and 
Gregory W. Rutecki. 
 
Abstract submitted to the American College of Physicians- American Society of 
Internal Medicine 2001 Associates Clinical Vignette and Research Competition 
 
6.   Fisher PW, Salloum F, Das A, Kukreja RC.  Type-5A Phosphodiesterase Inhibition 
Using Sildenafil (Viagra) Attenuates Cardiomyocyte Apoptosis and Left 
Ventricular Dysfunction in a Chronic Model of Doxorubicin-induced 
Cardiotoxicity. J Mol Cell Cardiol 2005 In Press 
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PUBLICATIONS 
 
1.  Decker, Robert S, Decker, Marlene L, Fisher, Patrick W, Nakamura, Sakie, Harris, 
Kathleen R, Klocke, Francis J.  Contribution of Apoptosis to the Contractile 
Dysfunction During Low-Flow Ischemia in the Canine Myocardium.  J Mol Cell 
Cardiol 2001; 33: A26. 
 
2. Fisher, PW, Ho, LT, Goldschmidt, R, Semerdjian, RJ, and Rutecki, GW. Familial                                    
Mediterranean Fever, Inflammation and Nephrotic Syndrome:  Fibrillary 
Glomerulopathy and the M680I Missense Mutation. BMC Nephrol, 2003; (4): p 6. 
 
3. Fisher PW, Salloum F, Das A, Hyder H, and Kukreja, RC. Phosphodiesterase-5 
Inhibition with Sildenafil Attenuates Cardiomyocyte Apoptosis and Left 
Ventricular Dysfunction in a Chronic Model of Doxorubicin Cardiotoxicity.  
Circulation, 2005; 111(13): 1601-1610. 
 
4. Kukreja RC, Salloum F, Das A, Ockaili R, Yin C, Bremer Y, Fisher PW, Wittkamp M, 
Hawkins J, Chou E, Kukreja A, Marwaha VR, Xi L. Pharmacological Preconditioning 
with Sildenafil: Basic Mechanisms and Clinical Implications.  Vascular Pharmacol, 
In Press, Corrected Proof, Available online 30 March 2005 
 
5. Wexler J, Fisher PW, Salloum F, Ockaili R, and Kukreja RC. Brain-Type Naturietic 
Pepdtide in Pharmacologic  Preconditioning: Role of Nitric Oxide and the 
Mitochondrial KATP Channel. 
 
Manuscript pending submission for publication-AJP(Heart-Circ) 
 
6. Okubo S, Fisher PW, Salloum F, Ockaili R, Marwaha VR, Guiseppe A, Hess ML, and 
Kukreja RC. Angiotensin II Receptor Blockade Reduces Apoptosis and Infarct Size 
in Ischemia/Reperfusion Injury in Rabbit Hearts.  JACC 2005; 45(3) Supplement A: 
p252A. 
 
7.  Fisher PW, Salloum F, Das A, Kukreja RC.  Type-5A Phosphodiesterase Inhibition 
Using Sildenafil (Viagra) Attenuates Cardiomyocyte Apoptosis and Left 
Ventricular Dysfunction in a Chronic Model of Doxorubicin-induced 
Cardiotoxicity. J Mol Cell Cardiol, 2005.  In Press. 
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BOOKS 
 
1. Patrick W. Fisher and Martin Schwarze, DO, FACC 
Clinical Cardiology:  Evidence-Based Medicine—A Guide to Advancements in 
Cardiovascular Medicine and  its Application in the Clinical Setting.  
! 1999-2000 KCOM Press, Inc.  
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PROFESSIONAL MEMBERSHIPS 
 
1.  American Medical Association 
 
2.  American Heart Association-Basic Cardiovascular Science Council 
 
3. International Society for Heart Research 
 
4. American Academy for the Advancement of Science 
 
5. American College of Cardiology 
 
6. Medical Society of Virginia 
 
7. American College of Physicians 
 
8. American Association for Cancer Research (AACR) 
 
9. International Cell Death Society 
 
10. Northwestern University Alumni Association 
 
11. National Postdoctoral Association 
 
12. International Society for Heart and Lung Transplantation 
 
13. Heart Failure Society of America 
 
14.  Kirksville College of Osteopathic Medicine Alumni Association 
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PROFESSIONAL EXPERIENCE 
 
Ad Hoc Committee for the Advancement of Medical Education 
Chairman (2001-2001) 
Evanston Northwestern Healthcare, Evanston, IL 
 
• Developed a proposal to acquire a HARVEY® patient simulator for the Department 
of Medicine (Spring 2001)  
 
• Purpose:  To enhance the physical diagnostic skills of residents, interns, and 
medical students through the coordination of bedside teaching with the UMEDIC®  
computer simulator and the HARVEY® patient simulator 
 
• Worked in coordination with the Department of Medicine and the Division of 
Cardiology in raising $100,000 for this project 
 
• Developed a core curriculum for the intensive and cardiac care unit rotations 
(Summer 2001) 
 
• HARVEY® and the UMEDIC®  program obtained (December 2001) 
 
 
Developed a proposal for the establishment of an endowment to provide financial 
resources to patients in the internal medicine outpatient department who are unable 
to afford necessary medications (Spring 2002) 
